

Supplemental Online Content

Raghu G, Richeldi L, Fernández Pérez ER, et al; ZEPHYRUS-1 Study Investigators. Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial. *JAMA*. Published online May 19, 2024. doi:10.1001/jama.2024.8693

eMethods

eFigure 1. ZEPHYRUS-1 Study Schema

eFigure 2. Change from Baseline in Forced Vital Capacity (mL): Subgroup Analyses

eTable 1. Prior Medications in the Main Study Cohort

eTable 2. Concomitant Medications for the Main Study Cohort

eTable 3. Important Protocol Deviations by Treatment

eTable 4. Change from Baseline in Forced Vital Capacity (mL): Subgroup Analyses

eTable 5. Change from Baseline in Forced Vital Capacity (mL) at Week 48: Interactions Between Stratification Groups

eTable 6. Change from Baseline in Forced Vital Capacity (mL) at Week 48: Observed vs. Imputed Data

eReference

This supplemental material has been provided by the authors to give readers additional information about their work.

eMethods

Study Design

Screening period:

All screening procedures were performed within 6 weeks prior to the first dose of study drug (Day 1). Study procedures performed during screening included provision of signed informed consent; assessment of inclusion/exclusion criteria; collection of demographic information; review of medical history; clinical laboratory assessments; assessment of vital signs and physical examination; electrocardiogram; recording of adverse events; recording of concomitant medications; recording of procedures and nondrug therapies; assessment of diffusing capacity of the lungs for carbon monoxide; pulmonary function tests; high-resolution computed tomography of the chest, completion of the St. George's Respiratory Questionnaire (SGRQ), the University of California San Diego – Shortness of Breath Questionnaire (UCSD–SOBQ), and the Leicester Cough Questionnaire (LCQ); and pregnancy test for women of child-bearing age.

Safety follow-up period:

Final safety assessments were performed 28 (± 7) and 60 (± 7) days after the last dose of study drug following completion of or early termination from the treatment period. At the 28-day in-person follow-up visit, clinical laboratory assessments were completed and vital signs were collected. Additionally, adverse events, concomitant medications, procedures, and nondrug therapies were recorded; patients completed the SGRQ, UCSD-SBQ, and LCQ; and women of child-bearing age completed a pregnancy test. At the 60-day follow-up via phone call, adverse events, and procedures and nondrug therapies were recorded, and the absence of pregnancy was confirmed for women of child-bearing age.

Patient Eligibility

Inclusion criteria:

1. Aged 40 to 85 years, inclusive, at screening initiation.
2. Diagnosis of idiopathic pulmonary fibrosis as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society guidelines.¹
3. Idiopathic pulmonary fibrosis diagnosis within the past 7 years, with onset defined as the date of the first recorded diagnosis of idiopathic pulmonary fibrosis by high-resolution computed tomography and/or surgical biopsy or other appropriate tissue sample (e.g., cryobiopsy) in the medical history.
4. Interstitial pulmonary fibrosis defined by high-resolution computed tomography scan at screening, with evidence of $\geq 10\%$ to $< 50\%$ parenchymal fibrosis (reticulation) and $< 25\%$ honeycombing, within the whole lung. **NOTE:** this requires confirmation by an independent radiology imaging review group prior to randomization. If a recent high-resolution computed tomography scan (within 3 months prior to screening) is available, it can be utilized for screening purposes, provided it is submitted and evaluated by the independent radiology imaging review group, is adhering to the imaging parameters detailed in the Imaging Core Manual, and is using the same accredited scanner as the on-study high-resolution computed tomography scans.
5. Percent-predicted forced vital capacity $> 45\%$ and $< 95\%$ at screening **and** Day 1 (prior to randomization).
6. Percent-predicted diffusing capacity of the lungs for carbon monoxide and corrected by hemoglobin value $\geq 25\%$ and $\leq 90\%$ at screening (determined locally). If a diffusing capacity of the lungs for carbon monoxide is available within 3 months prior to screening, it can be utilized for screening purposes.


7. Both forced vital capacity and diffusing capacity of the lungs for carbon monoxide testing must be representative of the idiopathic pulmonary fibrosis underlying disease (i.e., have been obtained in absence of an acute respiratory event [e.g., lung infection, cold] or other events that are known to affect pulmonary function testing results [e.g., broken rib, chest pain, other]).
8. Not currently receiving treatment for idiopathic pulmonary fibrosis with an approved therapy (i.e., pirfenidone or nintedanib) for any reason, including prior intolerance or lack of response to an approved idiopathic pulmonary fibrosis therapy, or choice to forego treatment with an approved idiopathic pulmonary fibrosis therapy after a full discussion with the investigator regarding risks/benefits of such therapy. **NOTE:** no participant should discontinue approved therapy for the purpose of enrolling in this study.
9. Male patients with partners of childbearing potential and female patients of childbearing potential (including those <1 year postmenopausal) must use a highly effective method of contraception per Clinical Trial Facilitation Group recommendation during the conduct of the study and for 3 months after the last dose of study drug. Women not of childbearing potential are defined as: a. Postmenopausal women (defined as at least 12 months with no menses without an alternative medical cause); in women <45 years of age, a high follicle stimulating hormone concentration in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; OR b. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR c. Have a congenital or acquired condition that prevents childbearing.
10. Able to understand and sign a written informed consent form.

Exclusion criteria:

1. Previous exposure to pamrevlumab.
2. Evidence of significant obstructive lung disease by any of the following criteria: (1) forced expiratory volume in 1 second/forced vital capacity ratio <0.70, or (2) extent of emphysema greater than the extent of fibrosis on high-resolution computed tomography. **NOTE:** this requires confirmation by an independent radiology imaging review group prior to randomization.
3. Female participants who are pregnant or nursing.
4. Smoking within 3 months of screening and/or unwilling to avoid smoking throughout the study.
5. Interstitial lung disease other than idiopathic pulmonary fibrosis, including but not limited to any of the other types of idiopathic interstitial pneumonias; lung diseases related to exposure to fibrogenic agents or other environmental toxins or drugs; other types of occupational lung diseases; granulomatous lung diseases; pulmonary vascular diseases; and systemic diseases, including vasculitis, infectious diseases, and connective tissue diseases. In cases of uncertain diagnosis, serological testing and/or review by multidisciplinary team should be performed to confirm diagnosis of idiopathic pulmonary fibrosis vs. other types of interstitial lung disease.
6. Sustained improvement in the severity of idiopathic pulmonary fibrosis during the 12 months prior to screening based on changes in forced vital capacity, diffusing capacity of the lungs for carbon monoxide, and/or high-resolution computed tomography scans of the chest.
7. History of other types of respiratory diseases, including diseases or disorders of the airways, lung parenchyma, pleural space, mediastinum, diaphragm, or chest wall that, in the opinion of the investigator, would impact the primary protocol endpoint or otherwise preclude the patient's participation in the study.
8. Medical conditions (e.g., myocardial infarction/stroke within the past 6 months) or logistical challenges that in the opinion of the investigator preclude the patient's adequate participation in the study.
9. Poorly controlled chronic heart failure (New York Heart Association Class 3 or above); clinical diagnosis of cor pulmonale (an alteration in the structure and function of the right ventricle of the heart secondary to a primary disorder of the respiratory system) requiring specific treatment; or severe pulmonary arterial hypertension requiring specific treatment that, in the opinion of the investigator, would preclude the patient's participation in the study.
10. Clinically important abnormal laboratory tests (including serum creatinine ≥ 1.5 x upper limit of normal, hemoglobin <10 g/dL, white blood cells <3,000/mm³, platelets <100,000/mm³, serum total bilirubin >1.5 x upper limit of normal, serum alanine aminotransferase or aspartate aminotransferase ≥ 2 x upper limit of normal, or serum alkaline phosphatase ≥ 2 x upper limit of normal).

11. Ongoing acute exacerbation of idiopathic pulmonary fibrosis or suspicion of such process during screening or randomization, including hospitalization due to acute exacerbation within 4 weeks prior to or during screening.
12. High likelihood of lung transplantation (in the opinion of the investigator) within 6 months after Day 1.
13. Use of any investigational drugs or unapproved therapies or participation in a clinical trial with an investigational new drug within 30 days prior to screening, or use of approved idiopathic pulmonary fibrosis therapies (i.e., pirfenidone or nintedanib) within 1 week prior to screening.
14. Daily use of phosphodiesterase-5 inhibitor drugs (e.g., sildenafil, tadalafil) except for treatment of severe pulmonary artery hypertension.
15. Any current malignancy (this does not include localized cancer such as basal or squamous cell carcinoma of skin). Any history of malignancy likely to result in mortality or requiring significant medical or surgical intervention within the next year.
16. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies, or to any component of the excipient.
17. Any condition (other than idiopathic pulmonary fibrosis) that is likely to result in the death of the patient within the next year.
18. The investigator judges that the patient will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, addiction, or any other relevant medical or psychiatric conditions.

eFigure 1. ZEPHYRUS-1 Study Schema




^aThe safety assessment conducted 28 days after the last dose of study drug was completed in person, and the final safety assessment conducted 60 days after the last dose was completed with a follow-up phone call.

TEAE, treatment-emergent adverse event; TESAЕ, treatment-emergent serious adverse event.


eFigure 2. Change from Baseline in Forced Vital Capacity (mL): Subgroup Analyses

A. Mean Forced Vital Capacity (mL) from Baseline to Week 48 According to Sex




Pamrevlumab (n)							
Male	132	117	116	116	116	106	104
Female	49	46	43	46	45	41	41
Placebo (n)							
Male	126	114	113	104	107	104	92
Female	49	45	46	45	46	44	39

B. Mean Forced Vital Capacity (mL) from Baseline to Week 48 According to Age Group




Pamrevlumab (n)							
≤64 years	41	34	33	34	35	29	30
65-74 years	77	70	67	70	69	65	65
≥75 years	63	59	59	58	57	53	50
Placebo (n)							
≤64 years	28	24	26	24	24	23	21
65-74 years	94	91	88	83	85	83	75
≥75 years	53	44	45	42	44	42	35

C. Mean Forced Vital Capacity (mL) from Baseline to Week 48 According to Race




Pamrevlumab (n)							
White	117	106	105	107	106	99	97
Other	64	57	54	55	55	48	48
Placebo (n)							
White	104	94	94	89	92	92	82
Other	71	65	65	60	61	56	49

D. Mean Forced Vital Capacity (mL) from Baseline to Week 48 According to Prior Use of Approved IPF Treatments




Pamrevlumab (n)							
Prior treatment - Yes	99	91	85	86	86	79	79
Prior treatment - No	82	72	74	76	75	68	66
Placebo (n)							
Prior treatment - Yes	94	84	85	78	82	76	66
Prior treatment - No	81	75	74	71	71	72	65

E. Mean Forced Vital Capacity (mL) from Baseline to Week 48 According to Use of Approved IPF Treatments During the Study




Pamrevlumab (n)							
Treatment during study - Yes	35	27	29	29	30	26	24
Treatment during study - No	146	136	130	133	131	121	121
Placebo (n)							
Treatment during study - Yes	27	26	25	24	25	20	17
Treatment during study - No	148	133	134	125	128	128	114

F. Mean Forced Vital Capacity (mL) from Baseline to Week 48 According to GAP Stage



Pamrevlumab (n)							
GAP stage I	66	60	58	58	60	55	55
GAP stage II	105	95	93	96	93	84	82
GAP stage III	10	8	8	8	8	8	8
Placebo (n)							
GAP stage I	66	61	62	58	59	57	55
GAP stage II	96	87	90	85	89	85	70
GAP stage III	13	11	7	6	5	6	6

G. Mean Forced Vital Capacity (mL) from Baseline to Week 48 Among Patients Who Died During the Study



Pamrevlumab (n)	23	17	14	13	14	7	3
Placebo (n)	23	19	15	13	15	10	1

FVC, forced vital capacity; GAP, Gender-Age-Pulmonary function; IPF, idiopathic pulmonary fibrosis.

eTable 1. Prior Medications in the Main Study Cohort

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Any prior medication	49 (27.1)	58 (33.1)
Adrenergics, inhalants	1 (0.6)	1 (0.6)
Budesonide; formoterol fumarate	1 (0.6)	1 (0.6)
Anesthetics, local	1 (0.6)	0
Lidocaine	1 (0.6)	0
Angiotensin II receptor blockers, combinations	1 (0.6)	0
Hydrochlorothiazide; losartan potassium	1 (0.6)	0
Angiotensin II receptor blockers, plain	2 (1.1)	0
Losartan	2 (1.1)	0
Antibiotics for topical use	1 (0.6)	0
Mupirocin	1 (0.6)	0
Antidepressants	1 (0.6)	0
Bupropion	1 (0.6)	0
Anti-gout preparations	1 (0.6)	0
Colchicine	1 (0.6)	0
Antihistamines for systemic use	1 (0.6)	4 (2.3)
Bepotastine besilate	1 (0.6)	2 (1.1)
Chlorphenamine maleate	1 (0.6)	0
Levocetirizine dihydrochloride	1 (0.6)	1 (0.6)
Epinastine hydrochloride	0	1 (0.6)
Fexofenadine hydrochloride	0	1 (0.6)
Hydroxyzine hydrochloride	0	1 (0.6)
Olopatadine hydrochloride	0	1 (0.6)
Antithrombotic agents	0	2 (1.1)
Acetylsalicylic acid	0	2 (1.1)
Ascorbic acid (vitamin C), including combinations	1 (0.6)	0
Ascorbic acid	1 (0.6)	0
Bacterial vaccines	2 (1.1)	2 (1.1)
Pneumococcal vaccine	1 (0.6)	0
Pneumococcal vaccine conjugate 13V (CRM197)	1 (0.6)	1 (0.6)
Pneumococcal vaccine polysaccharide 23V	0	1 (0.6)
Beta-blocking agents	1 (0.6)	1 (0.6)
Carvedilol	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Bisoprolol fumarate	0	1 (0.6)
Corticosteroids for systemic use, plain	3 (1.7)	2 (1.1)
Betamethasone	1 (0.6)	0
Methylprednisolone	1 (0.6)	0
Prednisone	1 (0.6)	0
Prednisolone	0	2 (1.1)
Corticosteroids, plain	1 (0.6)	0
Desonide	1 (0.6)	0
Cough suppressants and expectorants, combinations	0	2 (1.1)
Antimony potassium tartrate; <i>Glycyrrhiza</i> spp.; <i>Papaver somniferum</i> tincture	0	1 (0.6)
Chlorphenamine maleate; dihydrocodeine bitartrate; guaifenesin; methylephedrine hydrochloride-DL	0	1 (0.6)
Cough suppressants, excluding combinations with expectorants	3 (1.7)	4 (2.3)
Benzonatate	1 (0.6)	1 (0.6)
Codeine	1 (0.6)	1 (0.6)
Levodropropizine	1 (0.6)	0
Codeine phosphate	0	1 (0.6)
Dextromethorphan hydrobromide; lysozyme hydrochloride; potassium cresolsulfonate	0	1 (0.6)
Decongestants and other nasal preparations for topical use	1 (0.6)	0
Fluticasone	1 (0.6)	0
Drugs for peptic ulcer and GERD	1 (0.6)	3 (1.7)
Pantoprazole	1 (0.6)	0
Famotidine	0	1 (0.6)
Lansoprazole	0	2 (1.1)
Expectorants, excluding combinations with cough suppressants	1 (0.6)	0
Cineole; dipenten; pinene	1 (0.6)	0
High-ceiling diuretics	1 (0.6)	0
Furosemide	1 (0.6)	0
Hypnotics and sedatives	0	1 (0.6)
Melatonin	0	1 (0.6)
Lipid-modifying agents, combinations	1 (0.6)	0
Ezetimibe; rosuvastatin calcium	1 (0.6)	0
Lipid-modifying agents, plain	1 (0.6)	2 (1.1)
Atorvastatin	1 (0.6)	0
Fish oil	0	1 (0.6)
Rosuvastatin calcium	0	1 (0.6)
Macrolides, lincosamides and streptogramins	1 (0.6)	2 (1.1)
Azithromycin	1 (0.6)	2 (1.1)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Muscle relaxants, centrally acting agents	0	1 (0.6)
Baclofen	0	1 (0.6)
Other cardiac preparations	1 (0.6)	0
Ubidecarenone	1 (0.6)	0
Other mineral supplements	1 (0.6)	1 (0.6)
Zinc	1 (0.6)	0
Magnesium oxide	0	1 (0.6)
Other plain vitamin preparations	1 (0.6)	0
Vitamin E NOS	1 (0.6)	0
Other systemic drugs for obstructive airway diseases	1 (0.6)	3 (1.7)
Aminophylline; chlorphenamine maleate; methoxyphenamine hydrochloride; noscapine	1 (0.6)	0
Montelukast sodium	0	1 (0.6)
Theobromine	0	2 (1.1)
Quinolone antibacterials	2 (1.1)	1 (0.6)
Levofloxacin	2 (1.1)	1 (0.6)
Selective calcium channel blockers with mainly vascular effects	2 (1.1)	0
Amlodipine	1 (0.6)	0
Amlodipine besilate	1 (0.6)	0
Tetracyclines	0	2 (1.1)
Doxycycline	0	2 (1.1)
Unspecified herbal and traditional medicine	3 (1.7)	1 (0.6)
<i>Anemarrhena asphodeloides</i> rhizome; <i>Arctium lappa</i> fruit; <i>Artemisia annua</i> herb; calcium sulfate; <i>Ephedra sinica</i> herb; <i>Forsythia suspensa</i> fruit; <i>Fritillaria thunbergii</i> bulb; <i>Glycyrrhiza uralensis</i> root with rhizome; <i>Lonicera japonica</i> flower; <i>Mentha canadensis</i> herb; <i>Prunus armeniaca</i> seed; <i>Scutellaria baicalensis</i> root	1 (0.6)	0
<i>Angelica dahurica</i> root; <i>Arisaema</i> spp. tuber; <i>Bombyx mori</i> ; <i>Gastrodia elata</i> tuber; <i>Notopterygium</i> spp. root with rhizome; <i>Panax notoginseng</i> root; <i>Saposhnikovia divaricata</i> root; <i>Sauromatum giganteum</i> tuber	1 (0.6)	0
<i>Artemisia</i> spp.	1 (0.6)	0
<i>Atropa belladonna</i> herb liquid extract; borneol; camphor; diphenhydramine hydrochloride; menthol; methyl salicylate; thymol	1 (0.6)	0
<i>Ligusticum chuansiong</i> rhizome; <i>Salvia miltiorrhiza</i> root with rhizome	1 (0.6)	0
<i>Corydalis yanhusuo</i> tuber; <i>Ipomoea nil</i> seed	0	1 (0.6)
Vasodilators used in cardiac diseases	1 (0.6)	0
Glyceryl trinitrate	1 (0.6)	0
Viral vaccines	36 (19.9)	45 (25.7)
COVID-19 vaccine NRVV Ad (ChAdOx1 nCov-19)	11 (6.1)	13 (7.4)
Tozinameran	11 (6.1)	6 (3.4)
Elasomeran	5 (2.8)	14 (8.0)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
COVID-19 vaccine NRVV Ad26 (Gam-COVID-Vac); COVID-19 vaccine NRVV Ad5 (Gam-COVID-Vac)	4 (2.2)	15 (8.6)
COVID-19 vaccine inactivated (Vero)	3 (1.7)	1 (0.6)
Influenza vaccine	2 (1.1)	3 (1.7)
Influenza vaccine inactivated split 3V	2 (1.1)	0
COVID-19 vaccine inactivated (Vero) CZ02	1 (0.6)	2 (1.1)

GERD, gastroesophageal reflux disease; NOS, not otherwise specified; NRVV, non-replicating viral vector.

eTable 2. Concomitant Medications for the Main Study Cohort

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Any concomitant medication	181 (100.0)	175 (100.0)
ACE inhibitors, combinations	2 (1.1)	1 (0.6)
Amlodipine besilate; benazepril hydrochloride	1 (0.6)	0
Indapamide; perindopril erbumine	1 (0.6)	0
Benazepril; hydrochlorothiazide	0	1 (0.6)
ACE inhibitors, plain	18 (9.9)	12 (6.9)
Enalapril	8 (4.4)	5 (2.9)
Lisinopril	7 (3.9)	6 (3.4)
Benazepril hydrochloride	1 (0.6)	0
Perindopril	1 (0.6)	0
Ramipril	1 (0.6)	0
Perindopril arginine	0	1 (0.6)
Adrenergics for systemic use	4 (2.2)	0
Ambroxol hydrochloride; clenbuterol hydrochloride	1 (0.6)	0
Bambuterol hydrochloride	1 (0.6)	0
Salbutamol	1 (0.6)	0
Salbutamol sulfate	1 (0.6)	0
Adrenergics, inhalants	64 (35.4)	56 (32.0)
Salbutamol	20 (11.0)	12 (6.9)
Fluticasone propionate; salmeterol xinafoate	15 (8.3)	4 (2.3)
Salbutamol sulfate	15 (8.3)	14 (8.0)
Budesonide; formoterol fumarate	7 (3.9)	8 (4.6)
Fluticasone furoate; vilanterol trifenate	6 (3.3)	0
Umeclidinium bromide; vilanterol trifenate	4 (2.2)	5 (2.9)
Ipratropium bromide; salbutamol sulfate	3 (1.7)	2 (1.1)
Ipratropium; salbutamol	3 (1.7)	3 (1.7)
Salmeterol	3 (1.7)	4 (2.3)
Glycopyrronium bromide; indacaterol maleate	2 (1.1)	1 (0.6)
Olodaterol hydrochloride; tiotropium bromide	2 (1.1)	0
Budesonide; formoterol	1 (0.6)	0
Budesonide; formoterol fumarate dihydrate	1 (0.6)	0
Fluticasone furoate; umeclidinium bromide; vilanterol trifenate	1 (0.6)	7 (4.0)
Fluticasone furoate; vilanterol	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Fluticasone; salmeterol	1 (0.6)	0
Formoterol	1 (0.6)	3 (1.7)
Olodaterol	1 (0.6)	0
Terbutaline sulfate	1 (0.6)	4 (2.3)
Umeclidinium bromide; vilanterol	1 (0.6)	0
Beclometasone dipropionate; formoterol fumarate	0	1 (0.6)
Levosalmbutamol hydrochloride	0	1 (0.6)
Olodaterol hydrochloride; tiotropium bromide monohydrate	0	2 (1.1)
Olodaterol; tiotropium	0	1 (0.6)
Umeclidinium; vilanterol	0	2 (1.1)
Vilanterol	0	1 (0.6)
Agents for treatment of hemorrhoids and anal fissures for topical use	1 (0.6)	0
Cinchocaine hydrochloride; hydrocortisone	1 (0.6)	0
Aldosterone antagonists and other potassium-sparing agents	4 (2.2)	4 (2.3)
Spirolactone	4 (2.2)	4 (2.3)
All other non-therapeutic products	1 (0.6)	0
Ethylenediamine diacetate	1 (0.6)	0
All other therapeutic products	4 (2.2)	6 (3.4)
Calcium polystyrene sulfonate	1 (0.6)	2 (1.1)
Folinic acid	1 (0.6)	0
<i>Lactobacillus rhamnosus</i>	1 (0.6)	0
Sodium polystyrene sulfonate	1 (0.6)	0
Glutathione	0	2 (1.1)
Glycopyrronium bromide	0	1 (0.6)
Penhyclidine hydrochloride	0	1 (0.6)
Sugammadex sodium	0	1 (0.6)
Allergens	1 (0.6)	1 (0.6)
Allergens NOS	1 (0.6)	1 (0.6)
Aminoglycoside antibacterials	2 (1.1)	2 (1.1)
Amikacin sulfate	1 (0.6)	0
Gentamicin sulfate	1 (0.6)	0
Isepamicin sulfate	0	1 (0.6)
Neomycin	0	1 (0.6)
Anabolic steroids	0	2 (1.1)
7-keto-dehydroepiandrosterone	0	1 (0.6)
Danazol	0	1 (0.6)
Androgens	3 (1.7)	3 (1.7)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Testosterone cypionate	3 (1.7)	3 (1.7)
Anesthetics, general	4 (2.2)	7 (4.0)
Propofol	4 (2.2)	3 (1.7)
Remifentanyl hydrochloride	3 (1.7)	3 (1.7)
Etomidate	1 (0.6)	1 (0.6)
Fentanyl citrate	1 (0.6)	2 (1.1)
Ketamine hydrochloride	1 (0.6)	0
Fentanyl	0	3 (1.7)
Anesthetics, local	15 (8.3)	7 (4.0)
Lidocaine	8 (4.4)	3 (1.7)
Lidocaine hydrochloride	5 (2.8)	2 (1.1)
Chlorhexidine gluconate; lidocaine hydrochloride	1 (0.6)	1 (0.6)
Oxybuprocaine hydrochloride	1 (0.6)	0
Ropivacaine	1 (0.6)	0
Benzocaine; menthol	0	1 (0.6)
Dyclonine	0	1 (0.6)
Epinephrine; lidocaine hydrochloride	0	1 (0.6)
Epinephrine; lidocaine; tetracaine	0	1 (0.6)
Angiotensin II receptor blockers, combinations	13 (7.2)	12 (6.9)
Hydrochlorothiazide; valsartan	3 (1.7)	0
Amlodipine besilate; olmesartan medoxomil	2 (1.1)	3 (1.7)
Amlodipine besilate; fimasartan potassium trihydrate	1 (0.6)	0
Amlodipine besilate; valsartan	1 (0.6)	0
Amlodipine; olmesartan medoxomil	1 (0.6)	0
Amlodipine; valsartan	1 (0.6)	0
Candesartan cilexetil; hydrochlorothiazide	1 (0.6)	0
Hydrochlorothiazide; irbesartan	1 (0.6)	0
Hydrochlorothiazide; losartan potassium	1 (0.6)	1 (0.6)
Hydrochlorothiazide; telmisartan	1 (0.6)	0
Levamlodipine besilate; telmisartan	1 (0.6)	0
Sacubitril; valsartan	1 (0.6)	2 (1.1)
Amlodipine besilate; telmisartan	0	2 (1.1)
Amlodipine camsilate; losartan potassium	0	1 (0.6)
Amlodipine; olmesartan	0	1 (0.6)
Hydrochlorothiazide; losartan	0	1 (0.6)
Hydrochlorothiazide; olmesartan medoxomil	0	1 (0.6)
Angiotensin II receptor blockers, plain	47 (26.0)	38 (21.7)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Losartan	24 (13.3)	19 (10.9)
Valsartan	7 (3.9)	9 (5.1)
Losartan potassium	6 (3.3)	5 (2.9)
Candesartan cilexetil	3 (1.7)	1 (0.6)
Irbesartan	3 (1.7)	1 (0.6)
Candesartan	2 (1.1)	0
Olmesartan	2 (1.1)	0
Olmesartan medoxomil	2 (1.1)	2 (1.1)
Telmisartan	1 (0.6)	1 (0.6)
Fimasartan potassium trihydrate	0	1 (0.6)
Antacids	9 (5.0)	6 (3.4)
Almagate	4 (2.2)	2 (1.1)
Magnesium hydroxide	2 (1.1)	0
Magnesium oxide	2 (1.1)	1 (0.6)
Aluminum hydroxide; magnesium carbonate	1 (0.6)	1 (0.6)
Calcium carbonate	1 (0.6)	0
Aldioxa; aluminum hydroxide; magnesium hydroxide	0	1 (0.6)
Aluminum hydroxide gel, dried; magnesium trisilicate	0	1 (0.6)
Anti-acne preparations for systemic use	0	1 (0.6)
Isotretinoin	0	1 (0.6)
Antidementia drugs	5 (2.8)	4 (2.3)
Apoaequorin	2 (1.1)	0
Apoaequorin; colecalciferol	1 (0.6)	0
Donepezil hydrochloride	1 (0.6)	1 (0.6)
Memantine hydrochloride	1 (0.6)	0
Other antidementia drugs	1 (0.6)	0
Donepezil	0	1 (0.6)
Galantamine	0	1 (0.6)
Memantine	0	1 (0.6)
Rivastigmine	0	1 (0.6)
Anti-adrenergic agents, centrally acting	2 (1.1)	0
Clonidine	2 (1.1)	0
Anti-adrenergic agents, peripherally acting	2 (1.1)	1 (0.6)
Doxazosin mesilate	1 (0.6)	0
Urapidil hydrochloride	1 (0.6)	0
Urapidil	0	1 (0.6)
Antibacterials for systemic use	0	2 (1.1)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Antibiotics	0	2 (1.1)
Antibiotics for topical use	5 (2.8)	4 (2.3)
Mupirocin	2 (1.1)	0
Chlortetracycline hydrochloride	1 (0.6)	0
Doxycycline	1 (0.6)	0
Oyher antibiotics for topical use	1 (0.6)	1 (0.6)
Chloramphenicol	0	1 (0.6)
Ciprofloxacin hydrochloride	0	1 (0.6)
Fusidic acid	0	1 (0.6)
Anticholinergic agents	1 (0.6)	1 (0.6)
Benzatropine mesilate	1 (0.6)	0
Trihexyphenidyl hydrochloride	0	1 (0.6)
Antidepressants	24 (13.3)	21 (12.0)
Citalopram	5 (2.8)	1 (0.6)
Bupropion hydrochloride	3 (1.7)	1 (0.6)
Mirtazapine	3 (1.7)	3 (1.7)
Trazodone	3 (1.7)	5 (2.9)
Duloxetine	2 (1.1)	0
Fluoxetine hydrochloride	2 (1.1)	0
Sertraline	2 (1.1)	1 (0.6)
Sertraline hydrochloride	2 (1.1)	2 (1.1)
Amitriptyline	1 (0.6)	1 (0.6)
Bupropion	1 (0.6)	1 (0.6)
Escitalopram	1 (0.6)	2 (1.1)
Escitalopram oxalate	1 (0.6)	1 (0.6)
Fluoxetine	1 (0.6)	1 (0.6)
Lamotrigine	1 (0.6)	1 (0.6)
Nortriptyline hydrochloride	1 (0.6)	0
Venlafaxine hydrochloride	1 (0.6)	1 (0.6)
Vortioxetine hydrobromide	1 (0.6)	0
Amitriptyline hydrochloride	0	1 (0.6)
Citalopram hydrobromide	0	1 (0.6)
Tianeptine sodium	0	2 (1.1)
Trazodone hydrochloride	0	3 (1.7)
Antidiarrheal microorganisms	12 (6.6)	12 (6.9)
Probiotics NOS	6 (3.3)	3 (1.7)
<i>Bacillus subtilis</i> ; <i>Enterococcus faecium</i>	1 (0.6)	3 (1.7)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
<i>Bifidobacterium infantis</i>	1 (0.6)	0
<i>Bifidobacterium longum</i> ; <i>Enterococcus faecalis</i> ; <i>Lactobacillus acidophilus</i>	1 (0.6)	1 (0.6)
<i>Lactobacillus helveticus</i> ; <i>Lactobacillus rhamnosus</i>	1 (0.6)	0
<i>Lactobacillus rhamnosus</i>	1 (0.6)	0
<i>Saccharomyces boulardii</i>	1 (0.6)	2 (1.1)
<i>Bifidobacterium</i> NOS; <i>Lactobacillus</i> NOS	0	1 (0.6)
<i>Lactobacillus acidophilus</i>	0	1 (0.6)
<i>Lactobacillus</i> NOS	0	1 (0.6)
Anti-emetics and antinauseants	7 (3.9)	16 (9.1)
Ondansetron	3 (1.7)	10 (5.7)
Domperidone	1 (0.6)	1 (0.6)
Hyoscine	1 (0.6)	0
Prochlorperazine	1 (0.6)	0
Promethazine	1 (0.6)	0
Granisetron hydrochloride	0	1 (0.6)
Metoclopramide	0	2 (1.1)
Metoclopramide hydrochloride	0	1 (0.6)
Ramosetron hydrochloride	0	1 (0.6)
Anti-epileptics	2 (1.1)	4 (2.3)
Levetiracetam	1 (0.6)	2 (1.1)
Phenobarbital	1 (0.6)	0
Valproate sodium; valproic acid	1 (0.6)	1 (0.6)
Gabapentin	0	1 (0.6)
Oxcarbazepine	0	1 (0.6)
Valproate sodium	0	1 (0.6)
Antifibrinolytics	2 (1.1)	1 (0.6)
Tranexamic acid	1 (0.6)	1 (0.6)
Ulinastatin	1 (0.6)	0
Antifungals for systemic use	1 (0.6)	1 (0.6)
Terbinafine	1 (0.6)	0
Terbinafine hydrochloride	0	1 (0.6)
Antifungals for topical use	6 (3.3)	7 (4.0)
Betamethasone; clotrimazole	1 (0.6)	1 (0.6)
Ciclopirox	1 (0.6)	1 (0.6)
Ciclopirox olamine	1 (0.6)	0
Diflucortolone valerate; isoconazole nitrate	1 (0.6)	2 (1.1)
Ketoconazole	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Sertaconazole nitrate	1 (0.6)	1 (0.6)
Tioconazole	1 (0.6)	0
Clotrimazole	0	2 (1.1)
Clotrimazole; hydrocortisone	0	1 (0.6)
Fluconazole	0	1 (0.6)
Flutrimazole	0	1 (0.6)
Antiglaucoma preparations and miotics	1 (0.6)	5 (2.9)
Timolol	1 (0.6)	0
Travoprost	1 (0.6)	0
Bimatoprost	0	1 (0.6)
Brimonidine	0	1 (0.6)
Antiglaucoma preparations and miotics	1 (0.6)	5 (2.9)
Brimonidine tartrate	0	1 (0.6)
Dorzolamide hydrochloride; timolol maleate	0	1 (0.6)
Latanoprost	0	3 (1.7)
Timolol maleate	0	1 (0.6)
Anti-gout preparations	11 (6.1)	12 (6.9)
Allopurinol	8 (4.4)	7 (4.0)
Febuxostat	3 (1.7)	4 (2.3)
Colchicine	0	4 (2.3)
Antihistamines for systemic use	48 (26.5)	49 (28.0)
Loratadine	12 (6.6)	10 (5.7)
Levocetirizine dihydrochloride	7 (3.9)	12 (6.9)
Fexofenadine hydrochloride	6 (3.3)	6 (3.4)
Cetirizine hydrochloride	5 (2.8)	7 (4.0)
Cetirizine	4 (2.2)	3 (1.7)
Desloratadine	4 (2.2)	1 (0.6)
Chlorphenamine	3 (1.7)	1 (0.6)
Diphenhydramine hydrochloride	3 (1.7)	2 (1.1)
Fexofenadine	3 (1.7)	1 (0.6)
Bepotastine besilate	2 (1.1)	2 (1.1)
Chlorphenamine maleate	2 (1.1)	2 (1.1)
Diphenhydramine	2 (1.1)	4 (2.3)
Levocetirizine	2 (1.1)	1 (0.6)
Azelastine hydrochloride	1 (0.6)	0
Bepotastine salicylate	1 (0.6)	0
Bilastine	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Desloratadine citrate disodium	1 (0.6)	1 (0.6)
Ebastine	1 (0.6)	0
Hydroxyzine hydrochloride	1 (0.6)	2 (1.1)
Olopatadine hydrochloride	1 (0.6)	1 (0.6)
Promethazine	1 (0.6)	0
Bepotastine calcium dihydrate	0	1 (0.6)
Dexchlorpheniramine maleate	0	1 (0.6)
Emedastine fumarate	0	2 (1.1)
Epinastine hydrochloride	0	1 (0.6)
Ketotifen	0	1 (0.6)
Ketotifen fumarate	0	2 (1.1)
Mequitazine	0	2 (1.1)
Piprinhydrinate	0	1 (0.6)
Rupatadine fumarate	0	2 (1.1)
Anti-infectives	2 (1.1)	3 (1.7)
Anti-infectives, ophthalmic	1 (0.6)	0
Ofloxacin	1 (0.6)	0
Levofloxacin	0	1 (0.6)
Moxifloxacin	0	1 (0.6)
Tobramycin	0	1 (0.6)
Anti-infectives for systemic use	0	1 (0.6)
Andrographolide	0	1 (0.6)
Anti-inflammatory agents	2 (1.1)	2 (1.1)
Loteprednol etabonate	1 (0.6)	0
Prednisolone acetate	1 (0.6)	0
Fluorometholone	0	1 (0.6)
Ketorolac tromethamine	0	1 (0.6)
Prednisolone	0	1 (0.6)
Anti-inflammatory agents and anti-infectives in combination	0	1 (0.6)
Dexamethasone; tobramycin	0	1 (0.6)
Anti-inflammatory and antirheumatic products, non-steroids	53 (29.3)	48 (27.4)
Ibuprofen	21 (11.6)	21 (12.0)
Celecoxib	10 (5.5)	7 (4.0)
Diclofenac	5 (2.8)	3 (1.7)
Naproxen sodium	4 (2.2)	1 (0.6)
Meloxicam	3 (1.7)	6 (3.4)
Naproxen	3 (1.7)	3 (1.7)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Etoricoxib	2 (1.1)	1 (0.6)
Glucosamine	2 (1.1)	2 (1.1)
Loxoprofen sodium	2 (1.1)	0
Zaltoprofen	2 (1.1)	0
Aceclofenac	1 (0.6)	3 (1.7)
Arginine hydrochloride; ibuprofen	1 (0.6)	0
Chondroitin sulfate; glucosamine hydrochloride	1 (0.6)	0
Chondroitin; glucosamine	1 (0.6)	1 (0.6)
Diclofenac; vitamin B NOS	1 (0.6)	0
Indometacin	1 (0.6)	2 (1.1)
Ketoprofen	1 (0.6)	1 (0.6)
Ketorolac	1 (0.6)	1 (0.6)
Nabumetone	1 (0.6)	0
Pelubiprofen	1 (0.6)	0
Tetrandrine	1 (0.6)	0
Calcium carbonate; chondroitin sulfate; glucosamine hydrochloride	0	1 (0.6)
Chondroitin sulfate	0	1 (0.6)
Chondroitin sulfate; glucosamine sulfate	0	1 (0.6)
Dexibuprofen	0	2 (1.1)
Diclofenac sodium	0	2 (1.1)
Esomeprazole strontium; naproxen	0	1 (0.6)
Ketorolac tromethamine	0	2 (1.1)
Loxoprofen sodium dihydrate	0	2 (1.1)
Nimesulide	0	1 (0.6)
Other anti-inflammatory and antirheumatic agents, non-steroids	0	1 (0.6)
Sulfasalazine	0	1 (0.6)
Anti-inflammatory/antirheumatic agents in combination	1 (0.6)	1 (0.6)
Diphenhydramine citrate; ibuprofen	1 (0.6)	0
Betamethasone sodium phosphate; diclofenac potassium	0	1 (0.6)
Antimetabolites	1 (0.6)	1 (0.6)
Fluorouracil	1 (0.6)	1 (0.6)
Antimigraine preparations	1 (0.6)	0
Valproic acid	1 (0.6)	0
Antimycotics for systemic use	5 (2.8)	5 (2.9)
Fluconazole	3 (1.7)	2 (1.1)
Nystatin	2 (1.1)	2 (1.1)
Itraconazole	1 (0.6)	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Micafungin sodium	1 (0.6)	1 (0.6)
Voriconazole	1 (0.6)	1 (0.6)
Caspofungin acetate	0	1 (0.6)
Antinematodal agents	1 (0.6)	0
Ivermectin	1 (0.6)	0
Antipropulsives	6 (3.3)	4 (2.3)
Loperamide hydrochloride	4 (2.2)	1 (0.6)
Loperamide	2 (1.1)	3 (1.7)
Antipruritics, including antihistamines, anesthetics, etc.	1 (0.6)	1 (0.6)
Crotamiton	1 (0.6)	0
Boric acid; camphor; zinc oxide	0	1 (0.6)
Camphor	0	1 (0.6)
Antipsoriatics for topical use	1 (0.6)	1 (0.6)
Tapinarof	1 (0.6)	0
Betamethasone; tazarotene	0	1 (0.6)
Antipsychotics	4 (2.2)	2 (1.1)
Haloperidol lactate	1 (0.6)	0
Quetiapine	1 (0.6)	0
Quetiapine fumarate	1 (0.6)	1 (0.6)
Sulpiride	1 (0.6)	0
Ziprasidone	1 (0.6)	0
Aripiprazole	0	1 (0.6)
Antiseptics and disinfectants	1 (0.6)	1 (0.6)
Triclosan	1 (0.6)	0
Boric acid; glycerol	0	1 (0.6)
Antithrombotic agents	72 (39.8)	68 (38.9)
Acetylsalicylic acid	56 (30.9)	45 (25.7)
Apixaban	7 (3.9)	5 (2.9)
Clopidogrel	6 (3.3)	5 (2.9)
Clopidogrel bisulfate	6 (3.3)	9 (5.1)
Enoxaparin	4 (2.2)	3 (1.7)
Enoxaparin sodium	4 (2.2)	4 (2.3)
Heparin	3 (1.7)	2 (1.1)
Cilostazol	2 (1.1)	4 (2.3)
Acenocoumarol	1 (0.6)	2 (1.1)
Alprostadil	1 (0.6)	0
Cilostazol; ginkgo biloba leaf	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Clopidogrel resinate	1 (0.6)	0
Dabigatran etexilate mesilate	1 (0.6)	0
Ginkgo biloba; ticlopidine hydrochloride	1 (0.6)	0
Heparin sodium	1 (0.6)	1 (0.6)
Low molecular weight heparin, calcium salt	1 (0.6)	0
Low molecular weight heparin, sodium salt	1 (0.6)	0
Nadroparin calcium	1 (0.6)	1 (0.6)
Prasugrel	1 (0.6)	0
Rivaroxaban	1 (0.6)	2 (1.1)
Treprostinil	1 (0.6)	1 (0.6)
Warfarin	1 (0.6)	1 (0.6)
Acetylsalicylic acid; clopidogrel bisulfate	0	1 (0.6)
Cilostazol; ginkgo biloba	0	1 (0.6)
Edoxaban tosilate	0	1 (0.6)
Heparin; sodium chloride	0	1 (0.6)
Sarpogrelate hydrochloride	0	1 (0.6)
Ticagrelor	0	2 (1.1)
Treprostinil sodium	0	1 (0.6)
Triflusal	0	1 (0.6)
Antithyroid preparations	0	1 (0.6)
Thiamazole	0	1 (0.6)
Antivertigo preparations	0	5 (2.9)
Betahistine mesilate	0	2 (1.1)
Flunarizine dihydrochloride	0	1 (0.6)
Meclozine	0	2 (1.1)
Anxiolytics	33 (18.2)	17 (9.7)
Clonazepam	10 (5.5)	2 (1.1)
Alprazolam	8 (4.4)	9 (5.1)
Lorazepam	5 (2.8)	6 (3.4)
Buspirone	2 (1.1)	0
Buspirone hydrochloride	2 (1.1)	0
Diazepam	2 (1.1)	1 (0.6)
Amitriptyline hydrochloride	1 (0.6)	0
Duloxetine hydrochloride	1 (0.6)	0
Escitalopram	1 (0.6)	1 (0.6)
Etizolam	1 (0.6)	1 (0.6)
Hydroxyzine	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Oxazepam	1 (0.6)	0
Sertraline	1 (0.6)	1 (0.6)
Venlafaxine hydrochloride	1 (0.6)	0
Escitalopram oxalate	0	2 (1.1)
Appetite stimulants	5 (2.8)	3 (1.7)
Carnitine hydrochloride; cyanocobalamin; cyproheptadine orotate; lysine hydrochloride	3 (1.7)	1 (0.6)
Calcium phosphate; cyanocobalamin; cyproheptadine hydrochloride	1 (0.6)	0
Megestrol acetate	1 (0.6)	2 (1.1)
Arteriolar smooth muscle, agents acting on	2 (1.1)	1 (0.6)
Hydralazine	2 (1.1)	1 (0.6)
Ascorbic acid (vitamin C), including combinations	9 (5.0)	11 (6.3)
Ascorbic acid	9 (5.0)	11 (6.3)
Bacterial vaccines	3 (1.7)	4 (2.3)
Pneumococcal vaccine conjugate 13V (CRM197)	2 (1.1)	2 (1.1)
Pneumococcal vaccine polysaccharide 23V	1 (0.6)	1 (0.6)
Pneumococcal vaccine polyvalent	1 (0.6)	0
Typhoid vaccine polysaccharide VI	0	1 (0.6)
Belladonna and derivatives, plain	3 (1.7)	1 (0.6)
Cimetropium bromide	1 (0.6)	1 (0.6)
Hyoscine butylbromide	1 (0.6)	1 (0.6)
Hyoscyamine	1 (0.6)	0
Beta-blocking agents	39 (21.5)	39 (22.3)
Carvedilol	13 (7.2)	7 (4.0)
Metoprolol	8 (4.4)	6 (3.4)
Bisoprolol	6 (3.3)	4 (2.3)
Bisoprolol fumarate	5 (2.8)	6 (3.4)
Metoprolol succinate	5 (2.8)	4 (2.3)
Metoprolol tartrate	4 (2.2)	3 (1.7)
Nebivolol	2 (1.1)	1 (0.6)
Atenolol	1 (0.6)	5 (2.9)
Esmolol hydrochloride	1 (0.6)	0
Labetalol	1 (0.6)	0
Nebivolol hydrochloride	1 (0.6)	1 (0.6)
Arotinolol hydrochloride	0	1 (0.6)
Sotalol	0	1 (0.6)
Beta-lactam antibacterials, penicillins	27 (14.9)	32 (18.3)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Amoxicillin	14 (7.7)	11 (6.3)
Clavulanic acid	5 (2.8)	1 (0.6)
Amoxicillin; clavulanate potassium	4 (2.2)	1 (0.6)
Piperacillin sodium; tazobactam sodium	4 (2.2)	9 (5.1)
Piperacillin; tazobactam	3 (1.7)	4 (2.3)
Amoxicillin; clavulanic acid	2 (1.1)	3 (1.7)
Benzylpenicillin sodium	2 (1.1)	0
Amoxicillin sodium; clavulanate potassium	1 (0.6)	0
Amoxicillin trihydrate; clavulanate potassium	1 (0.6)	2 (1.1)
Amoxicillin trihydrate; clavulanic acid	1 (0.6)	0
Ampicillin	1 (0.6)	1 (0.6)
Phenoxymethylpenicillin potassium	1 (0.6)	0
Piperacillin sodium; sulbactam sodium	1 (0.6)	0
Ampicillin sodium; sulbactam sodium	0	1 (0.6)
Mezlocillin sodium	0	1 (0.6)
Piperacillin sodium; tazobactam	0	2 (1.1)
Sulbactam	0	1 (0.6)
Bile and liver therapy	2 (1.1)	2 (1.1)
Bicyclol	2 (1.1)	2 (1.1)
Bile therapy	1 (0.6)	4 (2.3)
Ursodeoxycholic acid	1 (0.6)	4 (2.3)
Blood and related products	4 (2.2)	2 (1.1)
Albumin human	4 (2.2)	2 (1.1)
Blood glucose-lowering drugs, excluding insulins	38 (21.0)	41 (23.4)
Metformin	23 (12.7)	15 (8.6)
Metformin hydrochloride	9 (5.0)	14 (8.0)
Sitagliptin phosphate	3 (1.7)	1 (0.6)
Empagliflozin	2 (1.1)	0
Glimepiride	2 (1.1)	6 (3.4)
Linagliptin	2 (1.1)	3 (1.7)
Alogliptin benzoate; pioglitazone hydrochloride	1 (0.6)	0
Canagliflozin	1 (0.6)	0
Dapagliflozin propanediol monohydrate	1 (0.6)	3 (1.7)
Gemigliptin tartrate	1 (0.6)	0
Gemigliptin tartrate sesquihydrate	1 (0.6)	0
Gliclazide	1 (0.6)	1 (0.6)
Glipizide	1 (0.6)	4 (2.3)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Gliquidone	1 (0.6)	0
Liraglutide	1 (0.6)	2 (1.1)
Lobeglitazone sulfate	1 (0.6)	0
Metformin hydrochloride; vildagliptin	1 (0.6)	0
Pioglitazone hydrochloride	1 (0.6)	2 (1.1)
Semaglutide	1 (0.6)	4 (2.3)
Sitagliptin	1 (0.6)	1 (0.6)
Acarbose	0	3 (1.7)
Alogliptin benzoate; metformin hydrochloride	0	1 (0.6)
Chromium picolinate; <i>Lagerstroemia speciosa</i> ; <i>Momordica charantia</i> ; pycnogenol	0	1 (0.6)
Dapagliflozin	0	1 (0.6)
Dulaglutide	0	1 (0.6)
Ertugliflozin	0	1 (0.6)
Gemigliptin tartrate; metformin hydrochloride	0	1 (0.6)
Glibenclamide	0	1 (0.6)
Glimepiride; metformin hydrochloride	0	1 (0.6)
Metformin hydrochloride; sitagliptin phosphate monohydrate	0	2 (1.1)
Pioglitazone	0	1 (0.6)
Repaglinide	0	1 (0.6)
Voglibose	0	2 (1.1)
Calcium	13 (7.2)	19 (10.9)
Calcium carbonate; colecalciferol	6 (3.3)	9 (5.1)
Calcium	2 (1.1)	4 (2.3)
Calcium carbonate	2 (1.1)	1 (0.6)
Calcium citrate	2 (1.1)	0
Calcium; magnesium; zinc	1 (0.6)	0
Calcium; vitamin D NOS	1 (0.6)	1 (0.6)
Boron; calcium; colecalciferol; copper; magnesium; manganese; zinc	0	1 (0.6)
Calcium citrate; colecalciferol	0	1 (0.6)
Calcium phosphate; cyanocobalamin; cyproheptadine	0	1 (0.6)
Calcium; colecalciferol	0	1 (0.6)
Capillary-stabilizing agents	1 (0.6)	0
Diosmin	1 (0.6)	0
Cardiac glycosides	2 (1.1)	1 (0.6)
Deslanoside	1 (0.6)	0
Digoxin	1 (0.6)	1 (0.6)
Cardiac stimulants, excluding cardiac glycosides	6 (3.3)	4 (2.3)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Epinephrine hydrochloride	2 (1.1)	1 (0.6)
Norepinephrine	2 (1.1)	3 (1.7)
Dopamine hydrochloride	1 (0.6)	0
Epinephrine	1 (0.6)	1 (0.6)
Isoprenaline hydrochloride	1 (0.6)	0
Midodrine	1 (0.6)	0
Norepinephrine bitartrate	1 (0.6)	1 (0.6)
Dopamine hydrochloride; glucose	0	1 (0.6)
Ephedrine	0	1 (0.6)
Phenylephrine	0	1 (0.6)
Chemotherapeutics for topical use	2 (1.1)	1 (0.6)
Metronidazole	2 (1.1)	1 (0.6)
Cicatrizants	1 (0.6)	1 (0.6)
Nepidermin	1 (0.6)	1 (0.6)
Corticosteroids	0	1 (0.6)
Dexamethasone sodium phosphate	0	1 (0.6)
Corticosteroids for systemic use, combinations	3 (1.7)	2 (1.1)
Betamethasone; desloratadine	2 (1.1)	0
Chlorphenamine; dexamethasone	1 (0.6)	0
Betamethasone; loratadine	0	1 (0.6)
Chlorphenamine maleate; dexamethasone	0	1 (0.6)
Corticosteroids for systemic use, plain	52 (28.7)	65 (37.1)
Prednisone	17 (9.4)	21 (12.0)
Methylprednisolone	9 (5.0)	13 (7.4)
Methylprednisolone sodium succinate	9 (5.0)	18 (10.3)
Meprednisone	8 (4.4)	6 (3.4)
Prednisolone	7 (3.9)	16 (9.1)
Triamcinolone acetonide	5 (2.8)	1 (0.6)
Betamethasone	4 (2.2)	2 (1.1)
Dexamethasone sodium phosphate	4 (2.2)	1 (0.6)
Prednisone acetate	4 (2.2)	2 (1.1)
Dexamethasone	3 (1.7)	6 (3.4)
Betamethasone acetate; betamethasone sodium phosphate	2 (1.1)	0
Fludrocortisone acetate	1 (0.6)	0
Hydrocortisone	1 (0.6)	1 (0.6)
Methylprednisolone acetate	1 (0.6)	0
Betamethasone dipropionate	0	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Hydrocortisone sodium succinate	0	1 (0.6)
Prednisolone acetate	0	1 (0.6)
Triamcinolone	0	1 (0.6)
Corticosteroids, other combinations	1 (0.6)	0
Clobetasol propionate; tretinoin	1 (0.6)	0
Corticosteroids, plain	18 (9.9)	17 (9.7)
Mometasone furoate	4 (2.2)	4 (2.3)
Triamcinolone acetonide	4 (2.2)	0
Betamethasone	3 (1.7)	0
Hydrocortisone	3 (1.7)	5 (2.9)
Clobetasol	2 (1.1)	0
Clobetasol propionate	2 (1.1)	2 (1.1)
Methylprednisolone aceponate	2 (1.1)	2 (1.1)
Desonide	1 (0.6)	1 (0.6)
Desoximetasone	1 (0.6)	0
Hydrocortisone butyrate	1 (0.6)	0
Prednicarbate	1 (0.6)	2 (1.1)
Prednisolone valeroacetate	1 (0.6)	0
Betamethasone dipropionate	0	1 (0.6)
Betamethasone valerate	0	1 (0.6)
Diflucortolone valerate	0	1 (0.6)
Fluocinonide	0	1 (0.6)
Triamcinolone	0	1 (0.6)
Triamcinolone acetonide acetate	0	1 (0.6)
Cough and cold preparations	5 (2.8)	0
Cough and cold preparations	5 (2.8)	0
Cough suppressants and expectorants, combinations	34 (18.8)	31 (17.7)
Ammonium chloride; chlorphenamine maleate; dihydrocodeine bitartrate; methylephedrine hydrochloride-DL	11 (6.1)	15 (8.6)
Chlorphenamine maleate; dihydrocodeine bitartrate; guaifenesin; methylephedrine hydrochloride-DL	5 (2.8)	2 (1.1)
Dextromethorphan hydrobromide; guaifenesin	4 (2.2)	6 (3.4)
Codeine; guaifenesin	3 (1.7)	3 (1.7)
Ammonia; benzoic acid; camphor; glycerol; <i>Glycyrrhiza</i> spp. root with rhizome; guaifenesin; <i>Illicium verum</i> oil; <i>Papaver somniferum</i> tincture	2 (1.1)	2 (1.1)
Ammonium chloride; chlorphenamine maleate; codeine phosphate; ephedrine hydrochloride	2 (1.1)	3 (1.7)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Ammonium chloride; chlorphenamine maleate; dihydrocodeine bitartrate; methylephedrine hydrochloride-DL; pelargonium sidoides	2 (1.1)	1 (0.6)
Codeine phosphate; guaifenesin	2 (1.1)	1 (0.6)
Guaifenesin; pholcodine; pseudoephedrine hydrochloride; triprolidine hydrochloride	2 (1.1)	0
Bromhexine hydrochloride; codeine phosphate	1 (0.6)	0
Carbocisteine; dextromethorphan	1 (0.6)	0
Codeine phosphate; <i>Platycodon grandiflorus</i> root	0	1 (0.6)
Cough suppressants, excluding combinations with expectorants	33 (18.2)	38 (21.7)
Benzonatate	10 (5.5)	10 (5.7)
Codeine phosphate	8 (4.4)	14 (8.0)
Codeine	5 (2.8)	12 (6.9)
Dextromethorphan hydrobromide	4 (2.2)	2 (1.1)
Levodropropizine	4 (2.2)	5 (2.9)
Dextromethorphan	3 (1.7)	1 (0.6)
Brompheniramine; dextromethorphan; pseudoephedrine	1 (0.6)	0
Chlorphenamine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride	1 (0.6)	0
Codeine; ethylmorphine; homatropine methylbromide	1 (0.6)	0
Codeine; promethazine	1 (0.6)	0
Dextromethorphan hydrobromide; ephedrine hydrochloride; promethazine hydrochloride	1 (0.6)	0
Dextromethorphan hydrobromide; lysozyme hydrochloride; potassium cresolsulfonate	1 (0.6)	0
Homatropine methylbromide; hydrocodone bitartrate	1 (0.6)	0
Chlorphenamine; hydrocodone	0	1 (0.6)
Codeine; phenylephrine; promethazine	0	1 (0.6)
Zipeprol dihydrochloride	0	3 (1.7)
Decongestants and anti-allergics	2 (1.1)	3 (1.7)
Bepotastine besilate	1 (0.6)	0
Olopatadine	1 (0.6)	0
Olopatadine hydrochloride	1 (0.6)	1 (0.6)
Epinastine hydrochloride	0	1 (0.6)
Ketotifen	0	1 (0.6)
Decongestants and other nasal preparations for topical use	23 (12.7)	25 (14.3)
Fluticasone propionate	8 (4.4)	7 (4.0)
Azelastine	3 (1.7)	1 (0.6)
Fluticasone	3 (1.7)	6 (3.4)
Fluticasone furoate	3 (1.7)	6 (3.4)
Budesonide	2 (1.1)	0
Azelastine hydrochloride	1 (0.6)	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Azelastine hydrochloride; fluticasone propionate	1 (0.6)	0
Ipratropium	1 (0.6)	0
Ipratropium bromide	1 (0.6)	2 (1.1)
Mometasone	1 (0.6)	0
Mometasone furoate	1 (0.6)	0
Mupirocin	1 (0.6)	0
Oxymetazoline hydrochloride	1 (0.6)	0
Sodium chloride	1 (0.6)	3 (1.7)
Triamcinolone acetonide	1 (0.6)	0
Camphor; menthol; methyl salicylate	0	1 (0.6)
Oxymetazoline	0	1 (0.6)
Sea water	0	1 (0.6)
Digestives, including enzymes	6 (3.3)	1 (0.6)
Enzyme preparations	2 (1.1)	0
Pancreatin	2 (1.1)	0
Alpha-D-galactosidase	1 (0.6)	0
Biodiastase 1000; cellulase; lipase; pancreatin; panprosin; simeticone; ursodeoxycholic acid	1 (0.6)	0
Pancreatin; simeticone; ursodeoxycholic acid	0	1 (0.6)
Direct-acting antivirals	15 (8.3)	14 (8.0)
Valaciclovir	5 (2.8)	1 (0.6)
Nirmatrelvir; ritonavir	4 (2.2)	1 (0.6)
Ganciclovir	2 (1.1)	1 (0.6)
Oseltamivir phosphate	2 (1.1)	4 (2.3)
Aciclovir	1 (0.6)	0
Azvudine	1 (0.6)	0
Peramivir	1 (0.6)	0
Tenofovir	1 (0.6)	1 (0.6)
Tenofovir alafenamide fumarate	1 (0.6)	0
Umifenovir	1 (0.6)	0
Cobicistat; darunavir ethanolate	0	1 (0.6)
Dolutegravir	0	1 (0.6)
Emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	0	1 (0.6)
Ganciclovir sodium	0	1 (0.6)
Lamivudine	0	1 (0.6)
Molnupiravir	0	1 (0.6)
Remdesivir	0	3 (1.7)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Ribavirin	0	1 (0.6)
Valaciclovir hydrochloride	0	1 (0.6)
Diuretics	0	1 (0.6)
Diuretics	0	1 (0.6)
Diuretics and potassium-sparing agents in combination	1 (0.6)	1 (0.6)
Furosemide; spironolactone	1 (0.6)	1 (0.6)
Dopaminergic agents	5 (2.8)	2 (1.1)
Carbidopa	1 (0.6)	0
Carbidopa monohydrate; levodopa	1 (0.6)	0
Carbidopa; levodopa	1 (0.6)	0
Levodopa	1 (0.6)	0
Pramipexole	1 (0.6)	0
Ropinirole hydrochloride	1 (0.6)	0
Benserazide hydrochloride; levodopa	0	1 (0.6)
Pramipexole dihydrochloride monohydrate	0	1 (0.6)
Drugs affecting bone structure and mineralization	9 (5.0)	3 (1.7)
Alendronate sodium	6 (3.3)	1 (0.6)
Denosumab	3 (1.7)	2 (1.1)
Drugs for constipation	25 (13.8)	17 (9.7)
Docusate sodium	5 (2.8)	1 (0.6)
Lactulose	5 (2.8)	1 (0.6)
Bisacodyl	4 (2.2)	1 (0.6)
Macrogol 3350	4 (2.2)	4 (2.3)
Macrogol	3 (1.7)	0
Glycerol	2 (1.1)	0
Magnesium oxide	2 (1.1)	1 (0.6)
Prucalopride succinate	2 (1.1)	0
Ascorbic acid; macrogol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate anhydrous	1 (0.6)	0
Docusate	1 (0.6)	0
Docusate sodium; sennoside a+b	1 (0.6)	0
Docusate sodium; sennosides NOS	1 (0.6)	0
Linaclotide	1 (0.6)	2 (1.1)
Magnesium hydroxide	1 (0.6)	3 (1.7)
Magnesium sulfate; potassium sulfate; sodium sulfate	1 (0.6)	0
Polycarbophil calcium	1 (0.6)	1 (0.6)
Sodium phosphate dibasic; sodium phosphate monobasic	1 (0.6)	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Sodium phosphate monobasic (anhydrous)	1 (0.6)	0
Bacillus subtilis; enterococcus faecium	0	2 (1.1)
Drugs for constipation	25 (13.8)	17 (9.7)
Docusate sodium; <i>Senna alexandrina</i>	0	1 (0.6)
Lubiprostone	0	1 (0.6)
Macrogol 4000; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate	0	1 (0.6)
Wheat dextrin	0	1 (0.6)
Drugs for functional gastrointestinal disorders	7 (3.9)	9 (5.1)
Simeticone	4 (2.2)	2 (1.1)
Dicycloverine	1 (0.6)	0
Dimeticone	1 (0.6)	0
Tiropramide hydrochloride	1 (0.6)	2 (1.1)
Trimebutine	1 (0.6)	3 (1.7)
Otilonium bromide	0	1 (0.6)
Phloroglucinol	0	1 (0.6)
Pinaverium bromide	0	1 (0.6)
Trimebutine maleate	0	2 (1.1)
Drugs for peptic ulcer and GERD	110 (60.8)	96 (54.9)
Omeprazole	44 (24.3)	36 (20.6)
Esomeprazole	15 (8.3)	12 (6.9)
Famotidine	15 (8.3)	13 (7.4)
Pantoprazole	15 (8.3)	20 (11.4)
Pantoprazole sodium sesquihydrate	8 (4.4)	14 (8.0)
Lansoprazole	7 (3.9)	12 (6.9)
Rebamipide	7 (3.9)	4 (2.3)
Lafutidine	5 (2.8)	2 (1.1)
Dexlansoprazole	3 (1.7)	3 (1.7)
Rabeprazole sodium	3 (1.7)	5 (2.9)
Sucralfate	3 (1.7)	2 (1.1)
Tegoprazan	3 (1.7)	2 (1.1)
Bismuth pectin	1 (0.6)	0
Bismuth subsalicylate	1 (0.6)	0
Calcium carbonate; sodium alginate; sodium bicarbonate	1 (0.6)	0
Cimetidine	1 (0.6)	1 (0.6)
Esomeprazole magnesium	1 (0.6)	1 (0.6)
Esomeprazole magnesium trihydrate	1 (0.6)	1 (0.6)
Esomeprazole magnesium; sodium bicarbonate	1 (0.6)	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Esomeprazole sodium	1 (0.6)	1 (0.6)
Esomeprazole strontium	1 (0.6)	2 (1.1)
Ilaprazole	1 (0.6)	1 (0.6)
Nizatidine	1 (0.6)	2 (1.1)
Omeprazole sodium	1 (0.6)	1 (0.6)
Polaprezinc	1 (0.6)	2 (1.1)
Rabeprazole	1 (0.6)	1 (0.6)
Ranitidine	1 (0.6)	0
Ranitidine hydrochloride	1 (0.6)	0
Sodium alginate	1 (0.6)	1 (0.6)
Omeprazole magnesium	0	1 (0.6)
Vonoprazan fumarate	0	1 (0.6)
Drugs for treatment of tuberculosis	0	1 (0.6)
Ethambutol	0	1 (0.6)
Isoniazid	0	1 (0.6)
Pyrazinamide	0	1 (0.6)
Rifampicin	0	1 (0.6)
Drugs used in addictive disorders	2 (1.1)	0
Nicotine polacrilex	2 (1.1)	0
Naltrexone	1 (0.6)	0
Drugs used in benign prostatic hypertrophy	34 (18.8)	23 (13.1)
Tamsulosin hydrochloride	14 (7.7)	7 (4.0)
Tamsulosin	11 (6.1)	11 (6.3)
Finasteride	5 (2.8)	2 (1.1)
Terazosin hydrochloride	3 (1.7)	0
Dutasteride	2 (1.1)	2 (1.1)
Doxazosin mesilate	1 (0.6)	0
Dutasteride; tamsulosin hydrochloride	1 (0.6)	0
Lycopene	1 (0.6)	0
Silodosin	1 (0.6)	1 (0.6)
Alfuzosin hydrochloride	0	1 (0.6)
Naftopidil	0	1 (0.6)
Tadalafil	0	2 (1.1)
Electrolytes with carbohydrates	1 (0.6)	0
Citric acid; glucose; potassium chloride; sodium bicarbonate; sodium chloride	1 (0.6)	0
Emollients and protectives	3 (1.7)	3 (1.7)
Urea	2 (1.1)	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Zinc oxide	1 (0.6)	0
Emollients and protectives	0	1 (0.6)
Vitamin E NOS	0	1 (0.6)
Estrogens	2 (1.1)	0
Estradiol	2 (1.1)	0
Expectorants, excluding combinations with cough suppressants	38 (21.0)	49 (28.0)
Acetylcysteine	22 (12.2)	33 (18.9)
Guaifenesin	8 (4.4)	6 (3.4)
Ambroxol hydrochloride	6 (3.3)	6 (3.4)
Erdosteine	6 (3.3)	8 (4.6)
Cineole; dipenten; pinene	4 (2.2)	9 (5.1)
Bromhexine hydrochloride	2 (1.1)	3 (1.7)
Sodium chloride	2 (1.1)	0
Carbocisteine	1 (0.6)	1 (0.6)
Ambroxol	0	2 (1.1)
Fudosteine	0	1 (0.6)
General nutrients	1 (0.6)	0
Nutrients NOS	1 (0.6)	0
Glycogenolytic hormones	2 (1.1)	0
Glucagon	2 (1.1)	0
High-ceiling diuretics	20 (11.0)	29 (16.6)
Furosemide	20 (11.0)	28 (16.0)
Torasemide	3 (1.7)	1 (0.6)
Hormonal contraceptives for systemic use	0	1 (0.6)
Megestrol acetate	0	1 (0.6)
Hormone antagonists and related agents	2 (1.1)	0
Anastrozole	1 (0.6)	0
Bicalutamide	1 (0.6)	0
Hormones and related agents	0	1 (0.6)
Estradiol	0	1 (0.6)
Hypnotics and sedatives	29 (16.0)	18 (10.3)
Melatonin	9 (5.0)	4 (2.3)
Zolpidem tartrate	7 (3.9)	3 (1.7)
Midazolam	4 (2.2)	6 (3.4)
Zopiclone	4 (2.2)	1 (0.6)
Temazepam	3 (1.7)	0
Zolpidem	3 (1.7)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Dexmedetomidine hydrochloride	2 (1.1)	1 (0.6)
Benzodiazepine related drugs	1 (0.6)	0
Diphenhydramine hydrochloride	1 (0.6)	0
Diphenhydramine hydrochloride; naproxen sodium	1 (0.6)	0
Diphenhydramine hydrochloride; paracetamol	1 (0.6)	1 (0.6)
Estazolam	1 (0.6)	4 (2.3)
Eszopiclone	1 (0.6)	0
Ramelteon	1 (0.6)	1 (0.6)
Promethazine	0	1 (0.6)
IV solution additives	6 (3.3)	7 (4.0)
Potassium chloride	5 (2.8)	4 (2.3)
Sodium bicarbonate	3 (1.7)	3 (1.7)
Magnesium sulfate	2 (1.1)	0
Calcium gluconate	1 (0.6)	2 (1.1)
Potassium phosphate monobasic	1 (0.6)	1 (0.6)
IV solutions	15 (8.3)	17 (9.7)
Sodium chloride	10 (5.5)	7 (4.0)
Calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate	2 (1.1)	1 (0.6)
Calcium chloride; potassium chloride; sodium chloride; sodium lactate	2 (1.1)	0
Calcium chloride; potassium chloride; sodium lactate	2 (1.1)	1 (0.6)
Alanine; arginine; aspartic acid; glutamic acid; glycylglutamine; glycyltyrosine; histidine; isoleucine; leucine; lysine acetate; methionine; phenylalanine; proline; serine; threonine; tryptophan; valine	1 (0.6)	0
Calcium chloride; glucose; potassium chloride; sodium chloride; sodium lactate	1 (0.6)	0
Glucose	1 (0.6)	1 (0.6)
Glucose; sodium chloride	1 (0.6)	0
Potassium phosphate dibasic; potassium phosphate monobasic	1 (0.6)	0
Triglycerides	1 (0.6)	0
Alanine; arginine; aspartic acid; calcium chloride dihydrate; glucose; glutamic acid; glycine; glycine max seed oil; histidine; isoleucine; leucine; lysine acetate; magnesium chloride hexahydrate; methionine; <i>Olea europaea</i> oil; phenylalanine; potassium chloride; proline; serine; sodium acetate trihydrate; sodium glycerophosphate; threonine; tryptophan; tyrosine; valine	0	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Alanine; arginine; aspartic acid; calcium chloride; glucose monohydrate; glutamic acid; glycine; glycine max seed oil; histidine hydrochloride; isoleucine; leucine; lysine hydrochloride; magnesium acetate tetrahydrate; medium-chain triglycerides; methionine; phenylalanine; potassium acetate; proline; serine; sodium acetate; sodium chloride; sodium hydroxide; sodium phosphate monobasic (dihydrate); threonine; tryptophan; valine; zinc acetate dihydrate	0	1 (0.6)
Alanine; arginine; aspartic acid; calcium chloride; glucose; glutamic acid; glycine; glycine max seed oil; histidine; isoleucine; leucine; lysine hydrochloride; magnesium sulfate; methionine; phenylalanine; potassium chloride; proline; serine; sodium acetate; sodium glycerophosphate; threonine; tryptophan; tyrosine; valine	0	1 (0.6)
Alanine; arginine; calcium chloride; fish oil; glucose; glycine; glycine max seed oil; histidine; isoleucine; leucine; lysine acetate; magnesium sulfate; medium-chain triglycerides; methionine; <i>Olea europaea</i> oil; phenylalanine; potassium chloride; proline; serine; sodium acetate; sodium glycerophosphate; taurine; threonine; tryptophan; tyrosine; valine; zinc sulfate	0	1 (0.6)
Alanine; arginine; cysteine hydrochloride monohydrate; glycine; histidine; isoleucine; leucine; lysine acetate; methionine; phenylalanine; phosphoric acid; proline; serine; threonine; tryptophan; valine	0	2 (1.1)
Amino acids NOS	0	1 (0.6)
Amino acids NOS; carbohydrates NOS; minerals NOS; vitamins NOS	0	1 (0.6)
Amino acids NOS; electrolytes NOS; glucose	0	1 (0.6)
Calcium gluconate; glucose; magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium citrate	0	2 (1.1)
Fish oil; glycine max seed oil; <i>Olea europaea</i> oil; triglycerides	0	1 (0.6)
Immunoglobulins	5 (2.8)	5 (2.9)
Immunoglobulin human normal	3 (1.7)	3 (1.7)
Anti-D immunoglobulin	1 (0.6)	0
Antiviral monoclonal antibodies	1 (0.6)	0
Casirivimab	0	2 (1.1)
Imdevimab	0	2 (1.1)
Immunostimulants	3 (1.7)	2 (1.1)
Interferon alfa-2b	1 (0.6)	0
Thymalfasin	1 (0.6)	2 (1.1)
Thymopentin	1 (0.6)	0
Transfer factor	1 (0.6)	1 (0.6)
Immunosuppressants	25 (13.8)	20 (11.4)
Pirfenidone	20 (11.0)	18 (10.3)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Mycophenolate mofetil	2 (1.1)	0
Azathioprine	1 (0.6)	0
Hydroxychloroquine sulfate	1 (0.6)	1 (0.6)
Infliximab	1 (0.6)	0
Thalidomide	1 (0.6)	3 (1.7)
Leflunomide	0	1 (0.6)
Insulins and analogues	13 (7.2)	15 (8.6)
Insulin glargine	4 (2.2)	3 (1.7)
Insulin	3 (1.7)	3 (1.7)
Insulin aspart	3 (1.7)	1 (0.6)
Insulin lispro	3 (1.7)	4 (2.3)
Insulin degludec	1 (0.6)	1 (0.6)
Insulin glargine; lixisenatide	1 (0.6)	0
Insulin glulisine	1 (0.6)	0
Isophane insulin	1 (0.6)	1 (0.6)
Insulin aspart; insulin aspart protamine (crystalline)	0	2 (1.1)
Insulin detemir	0	1 (0.6)
Insulin human	0	4 (2.3)
Intestinal adsorbents	1 (0.6)	2 (1.1)
Diosmectite	1 (0.6)	2 (1.1)
Intestinal anti-inflammatory agents	2 (1.1)	0
Budesonide	1 (0.6)	0
Mesalazine	1 (0.6)	0
Iron preparations	4 (2.2)	3 (1.7)
Ferrous sulfate	4 (2.2)	2 (1.1)
Ferric hydroxide polymaltose complex	0	1 (0.6)
Irrigating solutions	0	1 (0.6)
Glucose	0	1 (0.6)
Lipid-modifying agents, combinations	7 (3.9)	6 (3.4)
Ezetimibe; rosuvastatin calcium	3 (1.7)	2 (1.1)
Amlodipine besilate; olmesartan medoxomil; rosuvastatin calcium	1 (0.6)	0
Atorvastatin calcium trihydrate; ezetimibe	1 (0.6)	1 (0.6)
Atorvastatin calcium; ezetimibe	1 (0.6)	2 (1.1)
Ezetimibe; simvastatin	1 (0.6)	1 (0.6)
Lipid-modifying agents, plain	83 (45.9)	77 (44.0)
Atorvastatin	25 (13.8)	24 (13.7)
Atorvastatin calcium	19 (10.5)	15 (8.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Rosuvastatin	11 (6.1)	9 (5.1)
Simvastatin	10 (5.5)	10 (5.7)
Rosuvastatin calcium	7 (3.9)	6 (3.4)
Fish oil	5 (2.8)	6 (3.4)
Ezetimibe	2 (1.1)	6 (3.4)
Gemfibrozil	2 (1.1)	0
Lovastatin	2 (1.1)	0
Omega-3 NOS	2 (1.1)	2 (1.1)
Pravastatin	2 (1.1)	5 (2.9)
Alirocumab	1 (0.6)	0
Atorvastatin calcium trihydrate	1 (0.6)	0
Choline fenofibrate	1 (0.6)	0
Colecalciferol; docosahexaenoic acid; eicosapentaenoic acid	1 (0.6)	0
Colestyramine	1 (0.6)	1 (0.6)
Fenofibrate	1 (0.6)	4 (2.3)
Fish oil; omega-3 fatty acids	1 (0.6)	0
Omega-3 fatty acids	1 (0.6)	0
Omega-3-acid ethyl ester	1 (0.6)	2 (1.1)
Pitavastatin	1 (0.6)	0
Pitavastatin calcium	1 (0.6)	0
Salmon oil	1 (0.6)	1 (0.6)
Eicosapentaenoic acid ethyl ester	0	1 (0.6)
Evolocumab	0	1 (0.6)
Fenofibric acid	0	1 (0.6)
Fish oil; vitamin E NOS	0	1 (0.6)
Liver therapy, lipotropics	6 (3.3)	5 (2.9)
Adenine hydrochloride; bifendate; carnitine orotate; cyanocobalamin; liver; pyridoxine hydrochloride; riboflavin	3 (1.7)	2 (1.1)
Glutathione	2 (1.1)	1 (0.6)
Ornithine aspartate	2 (1.1)	1 (0.6)
Magnesium isoglycyrrhizinate	1 (0.6)	0
Allium sativum oil; dimethyl 4,4'-biphenyldicarboxylate	0	1 (0.6)
Cysteine hydrochloride monohydrate; glycyrrhizic acid, ammonium salt	0	1 (0.6)
Low-ceiling diuretics, excluding thiazides	3 (1.7)	1 (0.6)
Indapamide	2 (1.1)	1 (0.6)
Metolazone	1 (0.6)	0
Low-ceiling diuretics, thiazides	10 (5.5)	8 (4.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Hydrochlorothiazide	10 (5.5)	8 (4.6)
Macrolides, lincosamides and streptogramins	28 (15.5)	20 (11.4)
Azithromycin	18 (9.9)	12 (6.9)
Clindamycin	6 (3.3)	2 (1.1)
Clarithromycin	3 (1.7)	4 (2.3)
Erythromycin	3 (1.7)	0
Clindamycin palmitate hydrochloride	1 (0.6)	0
Clindamycin phosphate	1 (0.6)	0
Clindamycin hydrochloride	0	1 (0.6)
Roxithromycin	0	2 (1.1)
Spiramycin	0	1 (0.6)
Magnetic resonance imaging contrast media	0	1 (0.6)
Gadoteridol	0	1 (0.6)
Multivitamins, combinations	2 (1.1)	0
Ascorbic acid; betacarotene; biotin; calcium; chloride; chromium; copper; folic acid; iodine; lycopene; magnesium; manganese; molybdenum; nickel; nicotinic acid; pantothenic acid; phosphorus; potassium; pyridoxine hydrochloride; riboflavin; selenium; silicon; thiamine; vanadium; vitamin B12 NOS; vitamin D NOS; vitamin E NOS; vitamin K NOS; xantofyl; zinc	1 (0.6)	0
Folic acid; iron; vitamins NOS	1 (0.6)	0
Multivitamins, plain	1 (0.6)	2 (1.1)
Ascorbic acid; dexpanthenol; ergocalciferol; nicotinamide; pyridoxine hydrochloride; retinol; riboflavin sodium phosphate; thiamine hydrochloride; tocopherol	1 (0.6)	2 (1.1)
Muscle relaxants, centrally acting agents	6 (3.3)	3 (1.7)
Eperisone hydrochloride	2 (1.1)	1 (0.6)
Afloqualone	1 (0.6)	0
Baclofen	1 (0.6)	1 (0.6)
Cyclobenzaprine	1 (0.6)	0
Cyclobenzaprine hydrochloride	1 (0.6)	0
Pridinol	0	1 (0.6)
Muscle relaxants, peripherally acting agents	3 (1.7)	2 (1.1)
Atracurium besilate	1 (0.6)	0
Cisatracurium besilate	1 (0.6)	0
Rocuronium bromide	1 (0.6)	2 (1.1)
Suxamethonium chloride	1 (0.6)	2 (1.1)
Mydriatics and cycloplegics	0	1 (0.6)
Atropine sulfate	0	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Nasal decongestants for systemic use	10 (5.5)	8 (4.6)
Ebastine; pseudoephedrine hydrochloride	2 (1.1)	5 (2.9)
Phenylephrine hydrochloride	2 (1.1)	0
Pseudoephedrine	2 (1.1)	2 (1.1)
Pseudoephedrine hydrochloride; triprolidine hydrochloride	2 (1.1)	0
Desloratadine; pseudoephedrine sulfate	1 (0.6)	0
Loratadine; pseudoephedrine sulfate	1 (0.6)	0
Pseudoephedrine hydrochloride	1 (0.6)	0
Chlorphenamine maleate; ibuprofen; pseudoephedrine hydrochloride	0	1 (0.6)
Opioids	24 (13.3)	19 (10.9)
Morphine	5 (2.8)	7 (4.0)
Hydrocodone bitartrate; paracetamol	4 (2.2)	2 (1.1)
Tramadol	4 (2.2)	2 (1.1)
Paracetamol; tramadol hydrochloride	3 (1.7)	2 (1.1)
Codeine; paracetamol	2 (1.1)	0
Morphine sulfate	2 (1.1)	0
Oxycodone hydrochloride; paracetamol	2 (1.1)	1 (0.6)
Pethidine hydrochloride	2 (1.1)	0
Tramadol hydrochloride	2 (1.1)	4 (2.3)
Butorphanol tartrate	1 (0.6)	0
Codeine phosphate; doxylamine succinate; paracetamol	1 (0.6)	0
Fentanyl	1 (0.6)	1 (0.6)
Hydrocodone; paracetamol	1 (0.6)	1 (0.6)
Hydromorphone hydrochloride	1 (0.6)	1 (0.6)
Naloxone hydrochloride; oxycodone hydrochloride	1 (0.6)	1 (0.6)
Oxycodone	1 (0.6)	4 (2.3)
Codeine phosphate; paracetamol	0	1 (0.6)
Fentanyl citrate	0	1 (0.6)
Hydromorphone	0	1 (0.6)
Morphine hydrochloride	0	1 (0.6)
Pethidine	0	1 (0.6)
Other alimentary tract and metabolism products	4 (2.2)	4 (2.3)
Acetylcysteine	1 (0.6)	0
Lysine	1 (0.6)	0
Sodium bicarbonate	1 (0.6)	2 (1.1)
Thioctic acid	1 (0.6)	0
Resveratrol	0	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Ubidecarenone	0	1 (0.6)
Other analgesics and antipyretics	53 (29.3)	45 (25.7)
Paracetamol	36 (19.9)	32 (18.3)
Gabapentin	8 (4.4)	6 (3.4)
Acetylsalicylic acid	2 (1.1)	1 (0.6)
Acetylsalicylic acid; caffeine; paracetamol	2 (1.1)	1 (0.6)
Pregabalin	2 (1.1)	5 (2.9)
Acetylsalicylic acid; citric acid; sodium bicarbonate	1 (0.6)	0
Amantadine hydrochloride; caffeine; chlorphenamine maleate; cow bezoar; paracetamol	1 (0.6)	1 (0.6)
Bromhexine hydrochloride; chlorphenamine maleate; paracetamol; pseudoephedrine sulfate	1 (0.6)	3 (1.7)
Caffeine; paracetamol	1 (0.6)	0
Cannabidiol	1 (0.6)	0
Chlorphenamine maleate; dextromethorphan hydrobromide; paracetamol; pseudoephedrine hydrochloride	1 (0.6)	0
Dextromethorphan hydrobromide; paracetamol; phenylephrine hydrochloride	1 (0.6)	0
Dextromethorphan; guaifenesin; paracetamol; pseudoephedrine	1 (0.6)	0
Ibuprofen; paracetamol	1 (0.6)	0
Metamizole sodium	1 (0.6)	0
Nefopam hydrochloride	1 (0.6)	0
Propacetamol hydrochloride	1 (0.6)	1 (0.6)
Amitriptyline	0	1 (0.6)
Benorilate	0	1 (0.6)
Bromhexine; paracetamol; pseudoephedrine	0	1 (0.6)
Duloxetine	0	1 (0.6)
Duloxetine hydrochloride	0	1 (0.6)
Metamizole	0	1 (0.6)
Other antibacterials	6 (3.3)	11 (6.3)
Vancomycin	2 (1.1)	5 (2.9)
Colistimethate sodium	1 (0.6)	0
Colistin sulfate	1 (0.6)	0
Linezolid	1 (0.6)	0
Nitrofurantoin	1 (0.6)	1 (0.6)
Polymyxin B sulfate	1 (0.6)	0
Teicoplanin	1 (0.6)	0
Fenbufen; metronidazole	0	1 (0.6)
Metronidazole	0	3 (1.7)
Ornidazole	0	2 (1.1)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Other antihypertensives	3 (1.7)	4 (2.3)
Tadalafil	2 (1.1)	2 (1.1)
Sildenafil citrate	1 (0.6)	2 (1.1)
Other beta-lactam antibacterials	30 (16.6)	37 (21.1)
Ceftriaxone	7 (3.9)	6 (3.4)
Cefalexin	6 (3.3)	3 (1.7)
Ceftazidime	5 (2.8)	0
Cefepime	4 (2.2)	2 (1.1)
Cefdinir	3 (1.7)	3 (1.7)
Meropenem	3 (1.7)	0
Cefditoren pivoxil	2 (1.1)	9 (5.1)
Cefoperazone sodium; sulbactam sodium	2 (1.1)	2 (1.1)
Ceftriaxone sodium	2 (1.1)	2 (1.1)
Biapenem	1 (0.6)	1 (0.6)
Cefaclor	1 (0.6)	2 (1.1)
Cefcapene pivoxil hydrochloride hydrate	1 (0.6)	0
Cefixime	1 (0.6)	2 (1.1)
Cefoperazone; sulbactam	1 (0.6)	0
Cefpodoxime	1 (0.6)	0
Cefpodoxime proxetil	1 (0.6)	1 (0.6)
Ceftriaxone sodium sesquaterhydrate; sodium chloride	1 (0.6)	1 (0.6)
Cefuroxime sodium	1 (0.6)	0
Cilastatin sodium; imipenem	1 (0.6)	2 (1.1)
Flomoxef sodium	1 (0.6)	1 (0.6)
Meropenem trihydrate	1 (0.6)	4 (2.3)
Cefadroxil	0	1 (0.6)
Cefazolin	0	2 (1.1)
Cefepime hydrochloride	0	1 (0.6)
Cefoxitin	0	1 (0.6)
Cefoxitin sodium	0	1 (0.6)
Cefradine	0	1 (0.6)
Cefuroxime axetil	0	1 (0.6)
Ertapenem	0	1 (0.6)
Ertapenem sodium	0	1 (0.6)
Faropenem sodium	0	1 (0.6)
Methylol cefalexin lysinate	0	1 (0.6)
Other cardiac preparations	9 (5.0)	8 (4.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Ubidecarenone	5 (2.8)	2 (1.1)
Trimetazidine hydrochloride	2 (1.1)	1 (0.6)
Ivabradine hydrochloride	1 (0.6)	1 (0.6)
Ranolazine	1 (0.6)	3 (1.7)
Ivabradine	0	1 (0.6)
Other cold preparations	2 (1.1)	0
Chlorphenamine maleate; paracetamol; pseudoephedrine sulfate	2 (1.1)	0
Other dermatological preparations	3 (1.7)	1 (0.6)
Macrogol; propylene glycol; simeticone; sorbic acid; sorbitol; white soft paraffin	1 (0.6)	0
Pimecrolimus	1 (0.6)	0
Tacrolimus	1 (0.6)	0
Tretinoin	0	1 (0.6)
Other diagnostic agents	0	1 (0.6)
Indocyanine green	0	1 (0.6)
Other drugs for disorders of the musculoskeletal system	2 (1.1)	2 (1.1)
Bromelains	1 (0.6)	0
Hyaluronate sodium	1 (0.6)	1 (0.6)
Serrapeptase	1 (0.6)	0
Hyaluronic acid	0	1 (0.6)
Other drugs for obstructive airway diseases, inhalants	31 (17.1)	28 (16.0)
Ipratropium bromide	13 (7.2)	9 (5.1)
Budesonide	9 (5.0)	13 (7.4)
Tiotropium bromide monohydrate	3 (1.7)	1 (0.6)
Fluticasone	2 (1.1)	7 (4.0)
Fluticasone furoate	2 (1.1)	0
Fluticasone propionate	2 (1.1)	1 (0.6)
Ipratropium	2 (1.1)	2 (1.1)
Tiotropium bromide	2 (1.1)	0
Beclometasone dipropionate	1 (0.6)	0
Tiotropium	1 (0.6)	0
Umeclidinium	1 (0.6)	0
Umeclidinium bromide	1 (0.6)	0
Glycopyrronium bromide	0	1 (0.6)
Mometasone furoate	0	1 (0.6)
Other mineral supplements	12 (6.6)	12 (6.9)
Magnesium	5 (2.8)	4 (2.3)
Zinc	4 (2.2)	2 (1.1)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Selenium	2 (1.1)	0
Chromium	1 (0.6)	0
Magnesium amino acid chelate	1 (0.6)	0
Magnesium hydroxide	1 (0.6)	0
Magnesium; zinc	1 (0.6)	0
Manganese amino acid chelate; pyridoxine hydrochloride; zinc amino acid chelate	1 (0.6)	0
Manganese; zinc	1 (0.6)	0
Chromic chloride; copper sulfate; manganese sulfate; zinc sulfate	0	1 (0.6)
Magnesium chloride	0	1 (0.6)
Magnesium gluconate	0	1 (0.6)
Magnesium oxide	0	1 (0.6)
Zinc gluconate	0	2 (1.1)
Other nervous system drugs	3 (1.7)	3 (1.7)
Limaprost alfadex	2 (1.1)	0
Mecobalamin	1 (0.6)	1 (0.6)
Gabapentin	0	2 (1.1)
Other nutrients	2 (1.1)	2 (1.1)
Carbohydrates NOS; fats NOS; fiber, dietary; minerals NOS; proteins NOS; vitamins NOS	1 (0.6)	0
Casein; fats NOS; fiber, dietary; maltodextrin; minerals NOS; vitamins NOS	1 (0.6)	0
Casein; fiber, dietary; herbal oil NOS; maltodextrin; minerals NOS; vitamins NOS	1 (0.6)	0
Ascorbic acid; biotin; calcium; carbohydrates NOS; chloride; colestiferol; copper; cyanocobalamin; fats NOS; folic acid; iron; magnesium; manganese; nicotinamide; pantothenic acid; phosphorus; potassium; proteins NOS; pyridoxine; retinol; riboflavin; sodium; thiamine; tocopherol; zinc	0	1 (0.6)
Herbal NOS; minerals NOS; vitamins NOS	0	1 (0.6)
Other ophthalmologicals	13 (7.2)	8 (4.6)
Artificial tears [umbrella term]	4 (2.2)	0
Ciclosporin	3 (1.7)	1 (0.6)
Ascorbic acid; tocopheryl acetate; xantofyl; zeaxanthin; zinc	2 (1.1)	1 (0.6)
Hyaluronate sodium	2 (1.1)	1 (0.6)
Carbomer	1 (0.6)	0
Carmellose	1 (0.6)	1 (0.6)
Dextran 70	1 (0.6)	0
Hypromellose	1 (0.6)	0
Macrogol; propylene glycol	1 (0.6)	0
Potassium chloride; sodium chloride	1 (0.6)	0
Xantofyl; zeaxanthin	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Ascorbic acid; cupric oxide; dl-alpha tocopheryl acetate; xantofyl; zeaxanthin; zinc oxide	0	3 (1.7)
Carmellose sodium	0	1 (0.6)
Potassium iodide; sodium iodide	0	1 (0.6)
Other otologicals	0	1 (0.6)
Sodium bicarbonate	0	1 (0.6)
Other plain vitamin preparations	4 (2.2)	7 (4.0)
Biotin	2 (1.1)	4 (2.3)
Nicotinamide	1 (0.6)	0
Nicotinic acid	1 (0.6)	0
Pyridoxine hydrochloride	0	2 (1.1)
Vitamin E NOS	0	1 (0.6)
Other respiratory system products	3 (1.7)	1 (0.6)
Acetazolamide	1 (0.6)	0
Ambroxol	1 (0.6)	0
Lobeline hydrochloride	1 (0.6)	0
Nikethamide	1 (0.6)	0
Other respiratory system products	3 (1.7)	1 (0.6)
Ambroxol hydrochloride	0	1 (0.6)
Other systemic drugs for obstructive airway diseases	28 (15.5)	32 (18.3)
Theobromine	9 (5.0)	10 (5.7)
Montelukast sodium	8 (4.4)	9 (5.1)
Aminophylline; chlorphenamine maleate; methoxyphenamine hydrochloride; noscapine	7 (3.9)	15 (8.6)
Montelukast	4 (2.2)	2 (1.1)
Diprophylline	3 (1.7)	1 (0.6)
Doxofylline	3 (1.7)	6 (3.4)
Aminophylline; chlordiazepoxide; cholate sodium; ephedrine hydrochloride; promethazine hydrochloride	2 (1.1)	1 (0.6)
Ambroxol acefyllinate	1 (0.6)	1 (0.6)
Theophylline	1 (0.6)	0
Aminophylline	0	1 (0.6)
Other vitamin products, combinations	22 (12.2)	18 (10.3)
Vitamins NOS	17 (9.4)	16 (9.1)
Ascorbic acid; betacarotene; cupric oxide; tocopheryl acetate; zinc oxide	1 (0.6)	0
Ascorbic acid; biotin; cyanocobalamin; ferrous fumarate; folic acid; fursultiamine hydrochloride; nicotinamide; pyridoxine hydrochloride; riboflavin tetrabutryate; selenium; tocopheryl acetate; zinc oxide	1 (0.6)	0
Ascorbic acid; folic acid; selenium; tocopheryl acetate	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Colecalciferol; menaquinone-7	1 (0.6)	0
Minerals NOS; vitamins NOS	1 (0.6)	2 (1.1)
Ergocalciferol; phytomenadione; retinol palmitate; vitamin E NOS	0	1 (0.6)
Parasympathomimetics	2 (1.1)	4 (2.3)
Bethanechol chloride	2 (1.1)	1 (0.6)
Choline alfoscerate	0	3 (1.7)
Peripheral vasodilators	1 (0.6)	2 (1.1)
Dihydroergotoxine	1 (0.6)	0
Betahistine hydrochloride	0	1 (0.6)
Flunarizine dihydrochloride	0	1 (0.6)
Vincamine	0	1 (0.6)
Posterior pituitary lobe hormones	1 (0.6)	4 (2.3)
Vasopressin	1 (0.6)	1 (0.6)
Desmopressin	0	1 (0.6)
Desmopressin acetate	0	3 (1.7)
Potassium	11 (6.1)	14 (8.0)
Potassium chloride	8 (4.4)	11 (6.3)
Potassium	4 (2.2)	2 (1.1)
Potassium citrate	1 (0.6)	0
Magnesium aspartate; potassium aspartate	0	1 (0.6)
Propulsives	8 (4.4)	18 (10.3)
Mosapride citrate	5 (2.8)	15 (8.6)
Cinitapride	1 (0.6)	0
Itopride	1 (0.6)	0
Metoclopramide	1 (0.6)	2 (1.1)
Metoclopramide hydrochloride	1 (0.6)	0
Mosapride	1 (0.6)	0
Cinitapride tartrate; simeticone	0	1 (0.6)
Itopride hydrochloride	0	2 (1.1)
Protein kinase inhibitors	18 (9.9)	13 (7.4)
Nintedanib	9 (5.0)	6 (3.4)
Nintedanib esilate	9 (5.0)	7 (4.0)
Psycholeptics	0	1 (0.6)
Cannabidiol	0	1 (0.6)
Psycholeptics and psychoanaleptics in combination	0	1 (0.6)
Flupentixol dihydrochloride; melitracen hydrochloride	0	1 (0.6)
Psychostimulants, agents used for ADHD and nootropics	3 (1.7)	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Oxiracetam	3 (1.7)	0
Amphetamine aspartate; amphetamine sulfate; dexamphetamine saccharate; dexamphetamine sulfate	0	1 (0.6)
Quinolone antibacterials	22 (12.2)	38 (21.7)
Levofloxacin	13 (7.2)	21 (12.0)
Ciprofloxacin	5 (2.8)	7 (4.0)
Moxifloxacin hydrochloride	3 (1.7)	11 (6.3)
Levofloxacin lactate	1 (0.6)	1 (0.6)
Moxifloxacin	1 (0.6)	0
Gemifloxacin mesilate	0	1 (0.6)
Nemonoxacin malate	0	1 (0.6)
Selective calcium channel blockers with direct cardiac effects	9 (5.0)	7 (4.0)
Diltiazem	6 (3.3)	3 (1.7)
Diltiazem hydrochloride	4 (2.2)	2 (1.1)
Verapamil	0	1 (0.6)
Verapamil hydrochloride	0	1 (0.6)
Selective calcium channel blockers with mainly vascular effects	23 (12.7)	30 (17.1)
Amlodipine	13 (7.2)	14 (8.0)
Amlodipine besilate	8 (4.4)	7 (4.0)
Nifedipine	2 (1.1)	3 (1.7)
Amlodipine camsilate	1 (0.6)	0
Nicardipine	1 (0.6)	0
Nicardipine hydrochloride	1 (0.6)	1 (0.6)
Cilnidipine	0	1 (0.6)
Felodipine	0	2 (1.1)
Levamlodipine besilate	0	1 (0.6)
S-amlodipine nicotinate	0	2 (1.1)
Stomatological preparations	4 (2.2)	6 (3.4)
Nitrofurantoin	2 (1.1)	0
Chlorhexidine gluconate	1 (0.6)	2 (1.1)
Chlorhexidine gluconate; metronidazole	1 (0.6)	0
Glycerol	1 (0.6)	1 (0.6)
Nystatin	1 (0.6)	0
Cetylpyridinium chloride	0	1 (0.6)
Chlorhexidine	0	1 (0.6)
Sodium fluoride	0	1 (0.6)
Sulfonamides and trimethoprim	6 (3.3)	10 (5.7)
Sulfamethoxazole; trimethoprim	5 (2.8)	8 (4.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Trimethoprim	1 (0.6)	2 (1.1)
Sulfamethoxazole	0	2 (1.1)
Tetracyclines	10 (5.5)	11 (6.3)
Doxycycline	5 (2.8)	9 (5.1)
Minocycline hydrochloride	3 (1.7)	0
Doxycycline hyclate	2 (1.1)	3 (1.7)
Doxycycline; glucose	1 (0.6)	0
Tigecycline	1 (0.6)	1 (0.6)
Doxycycline hydrochloride	0	1 (0.6)
Doxycycline monohydrate	0	1 (0.6)
Throat preparations	3 (1.7)	2 (1.1)
Amylmetacresol; dichlorobenzyl alcohol	1 (0.6)	0
Benzocaine; <i>Eucalyptus globulus</i> oil; phenol; zinc oxide	1 (0.6)	0
Chlorhexidine	1 (0.6)	0
Benzocaine; <i>Mentha × piperita</i> oil; menthol	0	1 (0.6)
Phenol	0	1 (0.6)
Thyroid preparations	20 (11.0)	17 (9.7)
Levothyroxine	12 (6.6)	9 (5.1)
Levothyroxine sodium	7 (3.9)	7 (4.0)
Thyroid	1 (0.6)	1 (0.6)
Tonics	1 (0.6)	0
Dietary supplement	1 (0.6)	0
Topical products for joint and muscular pain	7 (3.9)	1 (0.6)
Diclofenac sodium	3 (1.7)	1 (0.6)
Camphor; menthol	1 (0.6)	0
Diclofenac	1 (0.6)	0
Magnesium chloride	1 (0.6)	0
Other topical products for joint and muscular pain	1 (0.6)	0
Unspecified herbal and traditional medicine	43 (23.8)	45 (25.7)
Unspecified herbal and traditional medicine	8 (4.4)	7 (4.0)
<i>Arctium lappa</i> fruit; cicada slough; <i>Ephedra</i> spp. herb; <i>Eriobotrya japonica</i> leaf; <i>Kitagawia praeurptora</i> root; <i>Perilla frutescens</i> fruit; <i>Perilla frutescens</i> leaf; <i>Pheretima</i> spp.;	6 (3.3)	1 (0.6)
<i>Schisandra chinensis</i> fruit		
<i>Cordyceps sinensis</i>	4 (2.2)	5 (2.9)
<i>Cordyceps sinensis</i> mycelium	4 (2.2)	4 (2.3)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
<i>Citrus maxima</i> peel; <i>Cynanchum</i> spp. root with rhizome; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Pinellia ternata</i> tuber; <i>Poria cocos</i> sclerotium; <i>Prunus</i> spp. seed; <i>Schisandra chinensis</i> fruit; <i>Stemona</i> spp. root tuber	3 (1.7)	1 (0.6)
<i>Coptis</i> spp. rhizome; <i>Hedera helix</i> leaf	3 (1.7)	5 (2.9)
<i>Corydalis yanhusuo</i> tuber; <i>Ipomoea nil</i> seed	3 (1.7)	3 (1.7)
<i>Artemisia</i> spp.	2 (1.1)	1 (0.6)
Calcium sulfate dihydrate; <i>Dryopteris crassirhizoma</i> rhizome; <i>Ephedra</i> spp. herb; <i>Forsythia suspensa</i> ; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Houttuynia cordata</i> herb; <i>Isatis tinctoria</i> root; <i>Lonicera japonica</i> flower; menthol; <i>Pogostemon cablin</i> herb; <i>Prunus</i> spp. seed; <i>Rheum</i> spp. root with rhizome; <i>Rhodiola crenulata</i> root with rhizome	2 (1.1)	3 (1.7)
<i>Eriobotrya japonica</i> leaf; menthol; <i>Morus alba</i> root bark; <i>Papaver somniferum</i> peel; <i>Platycodon grandiflorus</i> root; <i>Stemona sessilifolia</i> root tuber; <i>Vincetoxicum stauntonii</i> root with rhizome	2 (1.1)	0
<i>Plantago ovata</i>	2 (1.1)	3 (1.7)
<i>Aconitum pendulum</i> root tuber; benzoin; musk; <i>Oxytropis falcata</i> herb; <i>Phyllanthus emblica</i> fruit; <i>Rheum pumilum</i> herb; <i>Terminalia bellirica</i> fruit; <i>Terminalia chebula</i> fruit; <i>Tinospora sinensis</i> stem	1 (0.6)	0
<i>Acorus calamus</i> var. <i>angustatus</i> rhizome; <i>Anemarrhena asphodeloides</i> rhizome; calcium sulfate dihydrate; <i>Curcuma</i> spp. root tuber; <i>Forsythia suspensa</i> fruit; <i>Isatis tinctoria</i> root; <i>Phragmites australis</i> subsp. <i>australis</i> rhizome; <i>Pogostemon cablin</i> herb; <i>Rehmannia glutinosa</i> root tuber	1 (0.6)	1 (0.6)
<i>Aesculus hippocastanum</i> seed	1 (0.6)	0
<i>Albizia julibrissin</i> bark; <i>Areca catechu</i> seed; <i>Arisaema</i> spp. tuber; cicada slough; <i>Citrus aurantium</i> epicarp; <i>Citrus aurantium</i> submature fruit; <i>Citrus aurantium</i> unripe peel; <i>Magnolia officinalis</i> bark; <i>Massa medica</i> fermentum; <i>Oroxylum indicum</i> seed; <i>Perilla frutescens</i> stem; <i>Pinellia ternata</i> tuber; <i>Poria cocos</i> sclerotium; <i>Wurfbainia</i> spp. fruit; <i>Zingiber officinale</i> rhizome	1 (0.6)	0
<i>Allium sativum</i>	1 (0.6)	0
<i>Allium sativum</i> bulb; <i>Blumea balsamifera</i> leaf; <i>Crataegus pinnatifida</i> fruit; <i>Erigeron breviscapus</i> whole plant; <i>Ginkgo biloba</i> leaf; <i>Gynostemma pentaphyllum</i> herb; panax notoginseng root with rhizome; salvia miltiorrhiza root with rhizome	1 (0.6)	0
Ammonia; ammonium chloride; camphor; glycerol; <i>Glycyrrhiza</i> spp. root; guaifenesin	1 (0.6)	1 (0.6)
Ammonia; ammonium chloride; <i>Glycyrrhiza</i> spp. root with rhizome	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
<i>Angelica dahurica</i> root; <i>Artemisia annua</i> herb; <i>Bassia scoparia</i> fruit; cicada slough; <i>Cnidium monnieri</i> fruit; <i>Dictamnus dasycarpus</i> root bark; <i>Forsythia suspensa</i> fruit; <i>Gardenia jasminoides</i> fruit; <i>Gentiana</i> spp. root with rhizome; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Lonicera japonica</i> flower; <i>Phellodendron chinense</i> bark; <i>Pogostemon cablin</i> herb; <i>Rehmannia glutinosa</i> root tuber; <i>Scutellaria baicalensis</i> root; <i>Sophora flavescens</i> root	1 (0.6)	0
<i>Angelica pubescens</i> ; <i>Atractylodes macrocephala</i> ; <i>Boswellia serrata</i> ; <i>Eleutherococcus nodiflorus</i> ; <i>Eucommia ulmoides</i> ; <i>Gentiana macrophylla</i> ; <i>Salix alba</i> ; <i>Saposhnikovia divaricata</i>	1 (0.6)	0
Antelope horn; <i>Arctium lappa</i> fruit; calcium sulfate dihydrate; cow bezoar; <i>Descurainia sophia</i> seed; <i>Ephedra</i> spp. herb; <i>Lepidium apetalum</i> seed; <i>Pheretima</i> spp.; <i>Prunus</i> spp. seed	1 (0.6)	0
<i>Arctium lappa</i> fruit; ascorbic acid; chlorphenamine maleate; <i>Forsythia suspensa</i> fruit; <i>Glycine max</i> fermented seed; <i>Glycyrrhiza uralensis</i> root with rhizome; <i>Lonicera japonica</i> flower bud; <i>Lophatherum gracile</i> herb; <i>Mentha canadensis</i> oil; <i>Nepeta tenuifolia</i> herb;	1 (0.6)	0
paracetamol; <i>Phragmites australis</i> subsp. <i>australis</i> rhizome; <i>Platycodon grandiflorus</i> root <i>Areca catechu</i> seed; <i>Citrus aurantium</i> unripe fruit; <i>Dolomiaea costus</i> root; <i>Lindera aggregata</i> root	1 (0.6)	0
<i>Artemisia argyi</i> leaf	1 (0.6)	2 (1.1)
<i>Aster tataricus</i> root with rhizome; <i>Citrus aurantium</i> unripe fruit; <i>Ephedra</i> spp. stem; <i>Fagopyrum cymosum</i> rhizome; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Houttuynia cordata</i> whole plant; <i>Ilex chinensis</i> leaf; <i>Kitagawia praeurptora</i> root	1 (0.6)	0
<i>Aster tataricus</i> ; <i>Citrus aurantium</i> fruit peel; <i>Cynanchum</i> spp. root with rhizome; <i>Ephedra spp.</i> herb; <i>Kitagawia praeurptora</i> root; <i>Nepeta tenuifolia</i> herb; <i>Platycodon grandiflorus</i> root; <i>Prunus</i> spp. seed; <i>Saposhnikovia divaricata</i> root; <i>Stemona</i> spp. root tuber; <i>Tussilago farfara</i> flower	1 (0.6)	0
<i>Aster tataricus</i> ; <i>Glycyrrhiza uralensis</i> ; <i>Houttuynia cordata</i> ; <i>Inula helenium</i> ; <i>Marrubium vulgare</i> ; <i>Pinellia ternata</i> ; <i>Platycodon grandiflorus</i> ; <i>Stemona japonica</i> ; <i>Thymus vulgaris</i> oil	1 (0.6)	0
<i>Astragalus mongholicus</i> root; <i>Dalbergia odorifera</i> oil; <i>Panax notoginseng</i> root; <i>Salvia miltiorrhiza</i> root	1 (0.6)	0
<i>Astragalus mongholicus</i> root; <i>Panax notoginseng</i> root with rhizome; <i>Salvia miltiorrhiza</i> root with rhizome; <i>Scrophularia ningpoensis</i> root	1 (0.6)	0
<i>Atractylodes macrocephala</i> rhizome; <i>Cinnamomum cassia</i> twig; <i>Citrus aurantium</i> fruit peel; <i>Fossilia ossis mastodi</i> ; <i>Glycyrrhiza</i> spp. root with rhizome; oyster shell; <i>Pinellia ternata</i> tuber; <i>Platycodon grandiflorus</i> root; <i>Poria cocos</i> sclerotium; <i>Prunus</i> spp. seed; <i>Zingiber officinale</i> rhizome; <i>Ziziphus jujuba</i> fruit	1 (0.6)	0
<i>Atropa belladonna</i> herb liquid extract; borneol; camphor; diphenhydramine hydrochloride; menthol; methyl salicylate; thymol	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
<i>Atropa belladonna</i> ; boric acid; <i>Calamus draco</i> fruit resin; camphor; <i>Carthamus tinctorius</i> flower; diphenhydramine hydrochloride; musk; <i>Panax notoginseng</i> root with rhizome; procaine hydrochloride; <i>Salvia miltiorrhiza</i> root with rhizome; urea	1 (0.6)	0
Baicalin; buffalo horn; cholic acid; <i>Concha margaritifera</i> ; <i>Gardenia jasminoides</i> fruit; hyodeoxycholic acid; <i>Isatis tinctoria</i> root; <i>Lonicera japonica</i> flower	1 (0.6)	0
<i>Berberis kansuensis</i> bark; <i>Corydalis hendersonii</i> herb; fritillaria spp. bulb; <i>Gentiana scabra</i> root; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Inula racemosa</i> root; <i>Phlomis younghushandii</i> ; <i>Przewalskia tangutica</i> root; <i>Pseudocodon convolvulaceus</i> tuber; <i>Rhododendron</i> spp. leaf with flower	1 (0.6)	0
Borneol; <i>Cinnamomum cassia</i> bark; cow bezoar; <i>Liquidambar orientalis</i> balsam; musk; <i>Panax ginseng</i> root with rhizome; toad venom	1 (0.6)	2 (1.1)
Borneol; <i>Ligusticum chuanxiong</i> rhizome	1 (0.6)	1 (0.6)
Calcium sulfate dihydrate; <i>Descurainia sophia</i> seed; <i>Ephedra</i> spp. stem; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Papaver somniferum</i> pericarp; <i>Prunus</i> spp. seed; <i>Raphanus raphanistrum</i> subsp. <i>sativus</i> seed	1 (0.6)	0
Calcium sulfate dihydrate; <i>Ephedra</i> spp. stem; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Papaver somniferum</i> pericarp; <i>Platycodon grandiflorus</i> root; <i>Prunus</i> spp. seed; <i>Raphanus raphanistrum</i> subsp. <i>sativus</i> seed	1 (0.6)	0
<i>Calendula officinalis</i> ; carotenoids NOS; <i>Crocus sativus</i> ; phospholipids; <i>Ribes nigrum</i>	1 (0.6)	0
<i>Callicarpa nudiflora</i> leaf	1 (0.6)	1 (0.6)
Camphor; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Illicium verum</i> oil; <i>Papaver somniferum</i> latex; sodium benzoate	1 (0.6)	3 (1.7)
<i>Cannabis sativa</i>	1 (0.6)	0
<i>Cannabis sativa</i> fruit; <i>Citrus aurantium</i> submature fruit; <i>Magnolia officinalis</i> bark; <i>Paeonia lactiflora</i> root; <i>Prunus</i> spp. seed; <i>Rheum</i> spp. root with rhizome	1 (0.6)	0
Chlorphenamine maleate; <i>Ficus microcarpa</i> leaf	1 (0.6)	1 (0.6)
<i>Clematis</i> spp. extract; <i>Prunella vulgaris</i> extract; <i>Trichosanthes kirilowii</i> extract	1 (0.6)	0
<i>Corydalis bungeana</i> herb; <i>Isatis tinctoria</i> root; <i>Scutellaria baicalensis</i> root; <i>Taraxacum mongolicum</i> herb	1 (0.6)	0
<i>Cucurbita pepo</i> oil; lycopene; <i>Serenoa repens</i> fruit; <i>Vaccinium macrocarpon</i>	1 (0.6)	0
<i>Curcuma longa</i>	1 (0.6)	0
<i>Curcuma longa</i> rhizome	1 (0.6)	1 (0.6)
<i>Forsythia suspensa</i> fruit; <i>Ophiopogon japonicus</i> root tuber; <i>Rehmannia glutinosa</i> root tuber; <i>Scrophularia ningpoensis</i> root; <i>Scutellaria baicalensis</i> root	1 (0.6)	0
<i>Fritillaria</i> spp. bulb; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Mentha canadensis</i> herb; <i>Ophiopogon japonicus</i> root tuber; <i>Paeonia lactiflora</i> root; <i>Paeonia x suffruticosa</i> root bark; <i>Rehmannia glutinosa</i> root tuber; <i>Scrophularia ningpoensis</i> root	1 (0.6)	0

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
<i>Linum usitatissimum</i> seed oil	1 (0.6)	1 (0.6)
<i>Lycium barbarum</i>	1 (0.6)	0
<i>Phyllostachys nuda</i> stalk juice	1 (0.6)	0
<i>Plantago indica</i>	1 (0.6)	0
<i>Plantago ovata</i> husk	1 (0.6)	0
<i>Rhodiola chrysanthemifolia</i> subsp. <i>sacra</i>	1 (0.6)	0
<i>Ricinus communis</i> oil	1 (0.6)	0
<i>Senna alexandrina</i>	1 (0.6)	0
<i>Silybum marianum</i>	1 (0.6)	2 (1.1)
<i>Vitis vinifera</i>	1 (0.6)	0
<i>Abelmoschus manihot</i> flower	0	1 (0.6)
<i>Acorus calamus</i> var. <i>angustatus</i> rhizome; <i>Astragalus mongholicus</i> root; borneol; <i>Carthamus tinctorius</i> flower; <i>Curcuma</i> spp. root tuber; <i>Gastrodia elata</i> tuber; leech; <i>Ligusticum chuanxiong</i> rhizome; <i>Panax ginseng</i> root; <i>Ptyas dhumnades</i> ; <i>Pueraria montana</i> var. <i>lobata</i> root; <i>Salvia miltiorrhiza</i> root with rhizome	0	1 (0.6)
<i>Agrimonia pilosa</i> herb; <i>Forsythia suspensa</i> fruit; <i>Glycyrrhiza</i> spp. root with rhizome; indigo; <i>Paeonia x suffruticosa</i> root bark	0	1 (0.6)
Alum; <i>Boswellia</i> spp. resin; <i>Citrus aurantium</i> fruit peel; <i>Commiphora myrrha</i> resin; <i>Curcuma</i> spp. root tuber; <i>Glycyrrhiza</i> spp. root with rhizome; herbal NOS; <i>Lysimachia christinae</i> herb; potassium nitrate; <i>Rheum</i> spp. root with rhizome; <i>Sparganium stoloniferum</i> rhizome; swine bile	0	1 (0.6)
<i>Anemarrhena asphodeloides</i> rhizome; <i>Angelica dahurica</i> root; <i>Asarum</i> spp. root with rhizome; <i>Chrysanthemum indicum</i> flower head; <i>Ephedra</i> spp. stem; <i>Forsythia suspensa</i> fruit; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Magnolia</i> spp. flower bud; <i>Nepeta tenuifolia</i> herb; <i>Phellodendron chinense</i> bark; <i>Platycodon grandiflorus</i> root; <i>Saposhnikovia divaricata</i> root; <i>Schisandra chinensis</i> fruit; <i>Xanthium strumarium</i> subsp. <i>strumarium</i> fruit	0	1 (0.6)
<i>Angelica archangelica</i> root	0	1 (0.6)
<i>Angelica dahurica</i> root; <i>Artemisia argyi</i> leaf; <i>Bassia scoparia</i> fruit; <i>Cnidium monnieri</i> fruit; <i>Dictamnus dasycarpus</i> root bark; honeycomb; <i>Ligusticum chuanxiong</i> rhizome; <i>Nepeta tenuifolia</i> herb; <i>Portulaca oleracea</i> herb; <i>Prunus persica</i> twig; <i>Salix babylonica</i> twig; <i>Sophora flavescens</i> root; <i>Sophora tonkinensis</i> ; <i>Stemona</i> spp. root tuber; <i>Tamarix chinensis</i> ; <i>Tribulus terrestris</i> fruit	0	1 (0.6)
<i>Angelica sinensis</i> root; <i>Atractylodes macrocephala</i> rhizome; <i>Bupleurum</i> spp. root; <i>Citrus aurantium</i> submature fruit; <i>Citrus reticulata</i> unripe peel; <i>Codonopsis</i> spp. root; <i>Glycyrrhiza</i> spp. root with rhizome; <i>Imperata cylindrica</i> rhizome; <i>Massa medica</i> fermentum; <i>Paeonia lactiflora</i> root; <i>Pheretima</i> spp.; <i>Poria cocos</i> sclerotium; <i>Rubia cordifolia</i> root with rhizome; turtle carapace; <i>Wurfbainia</i> spp. fruit	0	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
<i>Arachis hypogaea</i> seed coat	0	1 (0.6)
<i>Artemisia scoparia</i> herb; bear bile; <i>Curcuma longa</i> ; <i>Dolomiaea costus</i> ; <i>Gentiana scabra</i> ; <i>Rheum officinale</i> ; <i>Terminalia chebula</i>	0	1 (0.6)
<i>Asparagus cochinchinensis</i> root tuber; <i>Canarium album</i> fruit; cicada slough; <i>Mentha canadensis</i> oil; <i>Ophiopogon japonicus</i> root tuber; <i>Oroxylum indicum</i> seed; <i>Paeonia x suffruticosa</i> bark; <i>Rehmannia glutinosa</i> root tuber; <i>Scrophularia ningpoensis</i> root; <i>Stemona spp.</i> root tuber; <i>Strobilanthes cusia</i> root with rhizome; <i>Tussilago farfara</i> flower bud	0	1 (0.6)
<i>Atractylodes macrocephala</i> rhizome; <i>Codonopsis spp.</i> root; <i>Glycyrrhiza spp.</i> root with rhizome; <i>Poria cocos</i> sclerotium	0	1 (0.6)
<i>Avena sativa</i>	0	1 (0.6)
<i>Bambusa spp.</i>	0	1 (0.6)
<i>Bassia scoparia</i> fruit; chlorhexidine diacetate; <i>Cnidium monnieri</i> fruit; <i>Dictamnus dasycarpus</i> root bark; <i>Gleditsia sinensis</i> spine (thorn, prickly); <i>Ilex rotunda</i> bark; <i>Mosla cavaleriei</i> herb; <i>Phellodendron chinense</i> bark; <i>Sauromatum giganteum</i> ; <i>Smilax glabra</i> rhizome; <i>Sophora flavescens</i> root; <i>Stemona spp.</i> root tuber; <i>Syzygium nervosum</i> bark	0	1 (0.6)
<i>Berberis vulgaris</i> root; <i>Camellia sinensis</i> leaf extract; <i>Coptis chinensis</i> root; <i>Curcuma longa</i> rhizome; origanum vulgare leaf; <i>Reynoutria japonica</i> root with rhizome; <i>Salvia rosmarinus</i> leaf; <i>Scutellaria baicalensis</i> root; <i>Zingiber officinale</i> rhizome	0	1 (0.6)
<i>Bidens biternata</i> ; caffeine; chlorphenamine maleate; <i>Chrysanthemum indicum</i> flower; <i>Ilex asprella</i> root; <i>Melicope pteleifolia</i> ; <i>Mentha canadensis</i> oil; paracetamol	0	2 (1.1)
Borneol; cicada slough; clorprenaline hydrochloride; decloxizine hydrochloride; <i>Elaeagnus pungens</i> leaf; <i>Glycyrrhiza spp.</i> root with rhizome; pearl; <i>Saposhnikovia divaricata</i> root; <i>Trichosanthes spp.</i> root	0	1 (0.6)
<i>Centella asiatica</i> herb	0	1 (0.6)
Centipede; <i>Curcuma longa</i> rhizome; <i>Curcuma spp.</i> root tuber; <i>Dioscorea oppositifolia rhizome</i> ; <i>Panax notoginseng</i> root with rhizome; <i>Rheum spp.</i> root with rhizome; <i>Schisandra chinensis</i> fruit; <i>Scutellaria baicalensis</i> root; <i>Tribulus terrestris</i> fruit	0	1 (0.6)
<i>Citrus aurantium</i> fruit peel; <i>Crataegus pinnatifida</i> fruit; <i>Dioscorea oppositifolia</i> rhizome; <i>Hordeum vulgare</i> sprout; <i>Pseudostellaria heterophylla</i> root tuber	0	1 (0.6)
<i>Cordyceps militaris</i>	0	1 (0.6)
<i>Eriobotrya japonica</i> leaf; menthol; <i>Morus alba</i> root bark; <i>Papaver somniferum</i> pericarp;	0	1 (0.6)
<i>Platycodon grandiflorus</i> root; <i>Stemona spp.</i> root tuber; <i>Vincetoxicum spp.</i> root with rhizome	0	1 (0.6)
<i>Ginkgo biloba</i> extract	0	2 (1.1)
<i>Ginkgo biloba</i> leaf dry extract	0	1 (0.6)
<i>Glycine max</i> ; <i>Persea americana</i> extract	0	1 (0.6)
<i>Glycyrrhiza spp.</i> root with rhizome; <i>Ophiopogon japonicus</i> root tuber; <i>Platycodon grandiflorus</i> root; <i>Scrophularia ningpoensis</i> root	0	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
<i>Grona styracifolia</i> herb; <i>Plantago asiatica</i> herb; <i>Pyrrosia lingua</i> leaf; <i>Zea mays</i> style	0	1 (0.6)
<i>Gynostemma pentaphyllum</i> herb total glycoside extract	0	1 (0.6)
<i>Hedera helix</i> extract	0	1 (0.6)
<i>Houttuynia cordata</i>	0	1 (0.6)
<i>Houttuynia cordata</i> whole plant	0	1 (0.6)
Krill oil	0	2 (1.1)
<i>Lonicera japonica</i> flower bud; <i>Scutellaria baicalensis</i> root	0	1 (0.6)
<i>Malus</i> spp. vinegar extract	0	1 (0.6)
<i>Monascus purpureus</i>	0	1 (0.6)
<i>Ophiopogon japonicus</i> root tuber; <i>Panax ginseng</i> root with rhizome; <i>Schisandra chinensis</i> fruit	0	1 (0.6)
<i>Pueraria montana</i> var. <i>lobata</i> root total flavonoid extract	0	1 (0.6)
<i>Punica granatum</i> seed	0	1 (0.6)
<i>Salvia hispanica</i> seed	0	1 (0.6)
<i>Salvia miltiorrhiza</i> root	0	1 (0.6)
<i>Urtica dioica</i> root	0	1 (0.6)
Urologicals	13 (7.2)	15 (8.6)
Mirabegron	2 (1.1)	5 (2.9)
Oxybutynin	2 (1.1)	1 (0.6)
Sildenafil	2 (1.1)	2 (1.1)
Botulinum toxin type A	1 (0.6)	0
Citric acid; sodium bicarbonate; sodium citrate; tartaric acid	1 (0.6)	0
Phenazopyridine	1 (0.6)	1 (0.6)
Piperazine ferulate	1 (0.6)	0
Sildenafil citrate	1 (0.6)	0
Tadalafil	1 (0.6)	1 (0.6)
Tolterodine L-tartrate	1 (0.6)	0
Alprostadil	0	1 (0.6)
<i>Escherichia coli</i>	0	1 (0.6)
Propiverine hydrochloride	0	2 (1.1)
Solifenacin succinate	0	1 (0.6)
Vibegron	0	1 (0.6)
Vasodilators used in cardiac diseases	12 (6.6)	12 (6.9)
Glyceryl trinitrate	6 (3.3)	7 (4.0)
Isosorbide mononitrate	4 (2.2)	4 (2.3)
Nicorandil	3 (1.7)	2 (1.1)
Isosorbide dinitrate	2 (1.1)	2 (1.1)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Viral vaccines	129 (71.3)	127 (72.6)
Tozinameran	57 (31.5)	52 (29.7)
Elasomeran	41 (22.7)	38 (21.7)
COVID-19 vaccine NRVV Ad (ChAdOx1 nCov-19)	29 (16.0)	30 (17.1)
Influenza vaccine	23 (12.7)	12 (6.9)
COVID-19 vaccine NRVV Ad26 (Gam-COVID-Vac); COVID-19 vaccine NRVV Ad5 (Gam-COVID-Vac)	11 (6.1)	9 (5.1)
COVID-19 vaccine inactivated (Vero)	8 (4.4)	9 (5.1)
COVID-19 vaccine inactivated (Vero) CZ02	4 (2.2)	3 (1.7)
Influenza vaccine inactivated split 3V	4 (2.2)	0
Influenza vaccine inactivated SAG 4v	3 (1.7)	4 (2.3)
COVID-19 vaccine NRVV Ad26 (JNJ 78436735)	2 (1.1)	0
Influenza vaccine inactivated SAG 3V	2 (1.1)	4 (2.3)
Influenza vaccine inactivated split 4V	2 (1.1)	5 (2.9)
COVID-19 vaccine inactivated (Vero) CQ01	1 (0.6)	0
Hepatitis vaccines	1 (0.6)	0
Varicella zoster vaccine	1 (0.6)	1 (0.6)
Varicella zoster vaccine rgE (CHO)	1 (0.6)	0
COVID-19 vaccine	0	1 (0.6)
COVID-19 vaccine inactivated (Vero) HB02	0	2 (1.1)
COVID-19 vaccine NRVV Ad5 (Ad5-nCov)	0	1 (0.6)
COVID-19 vaccine prot. subunit (NVX Cov 2373)	0	1 (0.6)
COVID-19 vaccine prot. subunit (ZF 2001)	0	1 (0.6)
Hepatitis A vaccine	0	1 (0.6)
Polio vaccine inactivated	0	1 (0.6)
Vitamins A and D, including combinations of the two	30 (16.6)	22 (12.6)
Colecalciferol	22 (12.2)	10 (5.7)
Vitamin D NOS	4 (2.2)	12 (6.9)
Calcitriol	3 (1.7)	1 (0.6)
Vitamins A and D, including combinations of the two	30 (16.6)	22 (12.6)
Cod liver oil	1 (0.6)	0
Vitamin B complex, including combinations	5 (2.8)	12 (6.9)
Aminobenzoic acid; biotin; calcium pantothenate; calcium phosphate dibasic; choline bitartrate; cyanocobalamin; folic acid; inositol; nicotinamide; pyridoxine hydrochloride; riboflavin; thiamine hydrochloride	1 (0.6)	0
Ascorbic acid; biotin; calcium; cyanocobalamin; folic acid; magnesium; nicotinamide; pantothenic acid; pyridoxine hydrochloride; riboflavin; thiamine hydrochloride; zinc	1 (0.6)	1 (0.6)

	Pamrevlumab (n=181), n (%)	Placebo (n=175), n (%)
Cyanocobalamin; dexpanthenol; nicotinamide; pyridoxine hydrochloride; riboflavin; thiamine hydrochloride	1 (0.6)	2 (1.1)
Vitamin B complex	1 (0.6)	8 (4.6)
Vitamin B NOS	1 (0.6)	0
Ascorbic acid; vitamin B complex	0	2 (1.1)
Vitamin B ₁ , plain and in combination with vitamin B ₆ and B ₁₂	3 (1.7)	1 (0.6)
Thiamine	2 (1.1)	0
Thiamine hydrochloride	1 (0.6)	0
Cyanocobalamin; pyridoxine hydrochloride; thiamine hydrochloride	0	1 (0.6)
Vitamin B ₁₂ and folic acid	18 (9.9)	5 (2.9)
Vitamin N ₁₂ NOS	9 (5.0)	2 (1.1)
Cyanocobalamin	7 (3.9)	2 (1.1)
Folic acid	5 (2.8)	2 (1.1)
Vitamin K and other hemostatics	4 (2.2)	3 (1.7)
Factor I (fibrinogen); thrombin	1 (0.6)	0
Haemocoagulase	1 (0.6)	0
Leucogen	1 (0.6)	1 (0.6)
Recombinant human thrombopoietin	1 (0.6)	0
Caffeic acid	0	1 (0.6)
Epinephrine	0	1 (0.6)
X-ray contrast media, iodinated	3 (1.7)	2 (1.1)
Iopamidol	3 (1.7)	0
Iohexol	0	2 (1.1)

ACE, angiotensin-converting enzyme; ADHD, attention deficit/hyperactivity disorder; CHO, Chinese hamster ovarian; GERD, gastroesophageal reflux disease; NOS, not otherwise specified.

eTable 3. Important Protocol Deviations by Treatment

Category of protocol deviation	Pamrevlumab (n=181)	Placebo (n=175)	Overall (N=356)
Overall IPD	30 (16.6)	26 (14.9)	56 (15.7)
Entry deviation	4 (2.2)	4 (2.3)	8 (2.2)
Dosing deviation	3 (1.7)	3 (1.7)	6 (1.7)
Prohibited medication	1 (0.6)	1 (0.6)	2 (0.6)
Operational deviation	23 (12.7)	19 (10.9)	42 (11.8)
COVID-19–related IPD	No observation	No observation	No observation

IPD, important protocol deviation.

eTable 4. Change from Baseline in Forced Vital Capacity (mL): Subgroup Analyses

		LS mean (SE) change		Absolute Difference (95% CI)	P Value
		Pamrevlumab (n=181)	Placebo (n=175)		
Prior use of approved therapy for idiopathic pulmonary fibrosis	<i>Yes</i>	<i>n=90 (49.7%)</i> -310.0 (64.0)	<i>n=77 (44.0%)</i> -390.0 (71.0)	80.0 (-100.0, 250.0)	.37
	<i>No</i>	<i>n=73 (40.3%)</i> -210.0 (70.0)	<i>n=72 (41.1%)</i> -260.0 (74.0)	50.0 (-120.0, 230.0)	.55
Use of approved antifibrotic treatments for idiopathic pulmonary fibrosis during the study	<i>Yes</i>	<i>n=29 (16.0%)</i> -380.0 (123.0)	<i>n=21 (12.0%)</i> -530.0 (175.0)	150.0 (-250.0, 550.0)	.46
	<i>No</i>	<i>n=134 (74.0%)</i> -240.0 (50.0)	<i>n=128 (73.1%)</i> -300.0 (510)	60.0 (-70.0, 190.0)	.35
Gender-Age-Pulmonary Function Score	<i>I</i>	<i>n=57 (31.5%)</i> -90.0 (42.0)	<i>n=58 (33.1%)</i> -190.0 (78.0)	100.0 (-80.0, 270.0)	.27
	<i>II</i>	<i>n=97 (53.6%)</i> -330.0 (65.0)	<i>n=79 (45.1%)</i> -300.0 (58.0)	-30.0 (-200.0, 130.0)	.68

		LS mean (SE) change		Absolute Difference (95% CI)	P Value
		Pamrevlumab (n=181)	Placebo (n=175)		
	<i>III</i>	<i>n=9 (5.0%)</i> 50.0 (907.0)	<i>n=12 (6.9%)</i> -600.0 (882.0)	660.0 (-70.0, 1380.0)	.07

LS, least-squares; SE, standard error.

eTable 5. Change from Baseline in Forced Vital Capacity (mL) at Week 48: Interactions Between Stratification Groups

Interaction	<i>P</i> Value
GAP stage and prior IPF treatment	0.29
GAP stage and race	0.29
GAP stage and sex	0.29
Prior IPF treatment and race	0.28
Prior IPF treatment and sex	0.29
Sex and race	0.29

eTable 6. Change from Baseline in Forced Vital Capacity (mL) at Week 48: Observed vs. Imputed Data

Data type	LS mean (SE) change		P Value
	Pamrevlumab (n=181)	Placebo (n=175)	
Observed data	<i>n</i> =145 -89.0 (236.8)	<i>n</i> =131 -129.0 (271.9)	0.19
Observed + imputed data	<i>n</i> =163 -256.0 (551.7)	<i>n</i> =149 -319.0 (608.2)	0.34

eReference

1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med*. 2018;198(5):e44-e68.